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The meshless method is an incredibly powerful technique for solving a variety of
problems with unparalleled accuracy and efficiency. The pharmacokinetic problem of
transdermal drug delivery (TDDD) is one such topic and is of significant complexity. The
locally collocated meshless method (LCMM) is developed in solution to this topic. First,
the meshless method is formulated to model this transport phenomenon and is then
validated against an analytical solution of a pharmacokinetic problem set, to demonstrate
this accuracy and efficiency. The analytical solution provides a locus by which
convergence behavior are evaluated, demonstrating the super convergence of the locally
collocated meshless method. An inverse method leveraging the LCMM is demonstrated,
providing a novel in silico technique that complements clinical research in determining
pharmacokinetic

parameters.

The

validation

and

inverse

problem

application

demonstrates the potential of the meshless framework in application to developing
treatments and therapies in the field of transdermal drug delivery.
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1. Introduction
The work here was motivated by a problem in industry: a pharmaceuticals company is
developing a topically delivered compound and need to ensure the delivery of an exact
concentration to the skin for patient safety. This is a problem of relative complexity, and
as engineers, we typically expect that a numerical solution can deliver answers to such
problems; to that end, a numerical method, particularly the Localized Collocation
Meshless Method (LCMM), is developed here to the solution of the pharmacokinetic
(PK) problem of dermally delivered compounds.
This dissertation straddles two fields; first and foremost, that of numerical methods and
second, pharmacokinetics, with the hope of merging the works and literature of the two
field towards the goal of delivering a foundational computational approach to the
transdermal pharmacokinetics problem. Consequently, it will be seen that each of these
fields will be surveyed separately; first, the physics behind pharmacokinetic process and
the resulting partial differential equations (PDEs) that model these physics, and second,
the numerical methods that may be able to model these processes efficiently. With the
pharmacokinetics fleshed out fully, the meshless method will be developed in application
to these physics, to arrive at a robust numerical framework that can support clinical
research in transdermal drug delivery (TDDD) efforts by providing in silico studies that
can be used in conjunction with empirical data.
The focus of the numerical methods sections will be on the meshless method, a rising
numerical technique which enjoys significant accuracy and stability improvements over
traditional numerical techniques. Admittedly, this focus might be perceived as bias,
instead, see it as the “sharing of something new and exciting” in the field of numerical
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methods. Meshless methods are something of a newcomer when compared to the history
of traditional methods, such as the finite differencing method (FDM) and finite element
method (FEM). However, the meshless method has a robust history of development
within our own research group, and others around the world, showing time and time
again its accuracy, efficiency and ease of implementation. The work here is particularly
aimed at extending the meshless method in solution of the pharmacokinetic model, and
reaping the benefits of such a strategy, to provide a holistic framework by which more
complex problems can be studied. Additionally, it is the authors hope to further the
acceptance and adoption of the meshless method by the industry of engineers and
scientists who work with numerical methods by further demonstrating its robustness,
accuracy and applicability across a range of fields
1.1. Significance of Study
This study seeks to develop and validate a numerical approach for addressing problems in
the field of transdermal drug delivery (TDDD). This work was initially motivated by one
particular problem in industry, however, the dermal transport of substances can be
applied to an incredible variety of therapeutic purposes; pain management, vaccination,
toxicity assessment, chronic condition management, and others [1]–[3]. In fact, TDDD
applications have increased rapidly, becoming a multi-billion dollar industry, with a
development rate more than tripling; before, new patches were being developed once
every 2.2 years, to now, being developed every 7.5 months [1], [4]. On first impressions,
these figures are indicative of how lucrative the field can be, but more importantly, it
indicates how much of an impact the field has in the realm of medicine.
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Additionally, it has been noted that there is a need for methods to characterize and
evaluate the performance of current and future TDDD systems [1]. Coincidentally, that is
exactly what the proposed work aims to do, creating a numerical framework to rapidly
characterize and evaluate dermal transport systems. Again, while the research here was
initially motivated by only a single problem in industry, the potential applications of a
robust numerical framework for the transdermal pharmacokinetic problem can have a
profound impact on the development of a wide range of current and future therapies.
1.2. Problem Statement
In essence, the problem at hand is that of modeling the diffusion-like process of dermal
transport of a compound in the skin [2], [4]–[7]. There are several complex, multiscale
physics involved in this process, and when combined with the intended temporal and
spatial scales of the problem, contributes to the difficulty in an efficient modeling
strategy, particularly as the analytical solutions of such problems are impractical and
border on the impossible. The desire is to produce a time-accurate field distribution of
any dermally transported compound, which, through inverse methods, will be leveraged
for the design of treatments. Surprisingly, there are quite few full-fledged diffusion
solutions to the pharmacokinetic problem set.
Unfortunately, the complexities of these solutions are especially pronounced in the
iterative strategies necessitated to support the various inverse problems required to
develop useful therapies. For example, of significance are the time and space scales at
which these processes play out; typically, spatial dimensions for these problems are in the
micro- to centimeter scale and solutions are sought over the course of hours or days [4].
Given Fourier stability limits at these scales, if one desires the solution to a single
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forward problem, then one can expect to iterate over approximately 15 solution steps, at
minimum, per simulated second. When recalling that these solutions are sought over 8 to
24 hours, sometimes even more, then the number of floating-point operations for a single
forward problem grows rapidly. In the context of inverse problems, which require
multiple forward solutions to arrive at some optima, then this quickly compounds the
number of floating-point operations over the study. Furthermore, if the study is targeting
an inverse geometry problem, which is a very reasonable expectation, then even more
overhead is incurred per solution when considering any domain preprocessing and mesh
generation requirements when traditional numerical methods are implemented.
1.3. Purpose Statement
In the most general sense, the goal of this work is to extend the meshless method in
application to pharmacokinetic modeling to aid in the development of TDDD systems.
This desire is to leverage the efficiency of the LCMM, which interestingly is a memoryminimizing method, to mitigate the ever-scaling number of calculations in the
pharmacokinetic problem set, as well as eliminating the need for time-intensive meshing
and domain preprocessing strategies associated with traditional numerical techniques.
The computational approach is aimed at providing in-silico studies as a part of, or in
complement to clinical pharmacokinetic research to fully-flesh details of the dermal
transport process that may be impractical or impossible to research via in vitro or in vivo
studies. The method is particularly developed to elaborate on the concentration of a
dermally transported compound and its spatial distribution within the dermis. That is, the
numerical method should be able to quantify the compound concentration at various
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coordinates within the dermal domain; allowing one to identify metrics and delivery
behavior that are important for developing guided tools for clinicians.
Given the obstacles expected of the computational pharmacokinetic problem, heavy
emphasis is placed on the efficiency of the method and ease of extensibility to inverse
and iterative problems. Of course, the method should allow for the gathering of
quantitative metrics to evaluate the performance of different TDDD systems, as well as
the fitness of solutions for application to inverse problems. While, storing the timehistory of a solution and gathering useful metrics from said solution is, relatively
speaking, a triviality in the scope of the approach presented, the numerical approach
presented here benefits from memory-minimizing characteristics of spectral methods.
1.4. Limitations and Assumptions
There are a variety of assumptions with regards to the pharmacokinetic modeling
considerations to deal with the complexity with the human skin, which is nonhomogenous, consisting of multiple layers and different phases within each layer, each
serving a separate purpose [2], [8], [9]. Most of these assumptions will be discussed in
detail in the literature review, however, they are worth stating now to provide a compact
reference for the reader.
First and foremost, dermal transport is fundamentally governed by a diffusion process
and will be modeled as such using the meshless method [2], [7], [10]. While full diffusion
has historically been simplified into a compartmental model, the compartmental model
does not provide the detail required for the type of research this numerical approach is
targeting. That is, the compartmental model does not provide the spatial variability of the
compound’s concentration in the skin, which is entirely the goal of this numerical
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development [11]–[13]. To implement a useable diffusion model, the assumption must be
made that each layer of the dermis is homogenous to the point of having a single
diffusion coefficient to describe it, with a different diffusion coefficient defining each
phase or compartment in the dermis. Future work may implement a diffusion coefficient
which varies spatially, but the current assumption is that each dermal layer has a nonvariable diffusion coefficient, an almost ubiquitous assumption in pharmacokinetic
modeling [2], [3], [10].
Skin is a non-homogenous media containing both hydrophilic and lipophilic components.
For simplicity, skin will be modeled as a biphasic media representing its hydrophilicity
and lipophilicity respectively [2], [8]. This behavior results in effects that are referred to
as partitioning and adsorption; which are accounted for in this work using a twocompartment model, representing the bound or unbound states of a compound as it
diffuses through the dermis [2], [10], [14]. Note that this is an entirely different
phenomenon from the “compartmental approach to diffusion.” Again, further detail will
be given in the literature review to expound on this distinction.
Metabolic activity of live cells in the dermis has significant impacts on the transport of
compounds through the skin. These metabolic effects and clearance effects, such as those
relating to solute removal due the micro capillary system, must be considered as part of
the modeling approach given their significance [2], [10], [15], [16]. These elimination
effects are modeled here using first-order kinetics.
In all of the studies presented, Verapamil is the compound transported in evaluating
various characteristics of the numerical framework. This is because Verapamil is a well-
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studied compound with significant works detailing the various pharmacokinetic
parameters of the compound.
List of Acronyms
BEM
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2. Review of the Relevant Literature
The two major areas of the literature review are, first, the pharmacokinetic and dermal
transport process and their underlying multiphysics phenomenon, and second, numerical
methods, particularly as pertains to the meshless method.
2.1. Pharmacokinetic Modeling
When dermal transport kinetics, as well as their limitations and assumptions, are well
understood, the modeling approach can be tailored to account for the various physical
phenomenon encountered in these problems. Thus, these underlying physics will be first
defined as they provide the governing equations to which the numerical method will be
applied. The primary processes accounted for and included in this work include the
diffusive effects, partitioning and adsorption kinetics and general elimination effects,
including metabolism and capillary clearance. A general note will be made with regards
to boundary effects and their impacts on the modeling approach, as these have direct
impacts on how accurate-to-life a simulation may be.
2.1.1. Diffusion Effects
At its foundation, dermal transport processes are governed by diffusive effects [2], [7],
[10], [11], [17]. Following Fick’s first law, the one-dimensional flux per unit area, 𝐽, of
substance transported by diffusion through a solvent is given as:
𝐽 = −𝐷

𝜕𝑐
𝜕𝑥

Where:
𝐽 = One dimensional flux per unit area, [𝑚𝑔/𝑐𝑚 𝑠]
𝐷 = Diffusion coefficient, [𝑐𝑚 /𝑠]
𝑐 = Compound concentration, [𝑚𝑔/𝑚𝐿]

(1)
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By accounting for the accumulation or mass conservation of the substance, one arrives at
the one-dimensional, transient diffusion equation, Fick’s second law, which provides the
backbone of the pharmacokinetic governing equations:
𝜕𝑐
𝜕 𝑐
=𝐷
𝜕𝑡
𝜕𝑥

(2)

Abstracting this to the general, multi-dimensional case, Fick’ second law appears as:
𝜕𝑐
= 𝐷𝛻 𝑐
𝜕𝑡

(3)

This formulation inherently implies that the skin, and the diffusion process within it, is to
be modeled as a continuum. This representation imposes an added complexity to the
solution of the governing equations, as it requires solving a set of partial differential
equations (PDE’s) over the domain. With numerical approaches, this then requires
satisfying the governing equations at all points within the domain; also requiring enough
points to achieve numerical stability of the solution over the domain. The complexity
posed by a continuum solution is circumnavigated through the implementation of the
compartmental model.
The compartmental model treats the tissue domain as a series of well-stirred
compartments, with each compartment having a uniformly distributed concentration of
the solute [11], [13], [18]. The compartmental model stacks several compartments to
account for depth-wise concentration variation; as the compound transports from one
compartment to another, the concentration within a compartment is indicative of the
depth of penetration of the compound under evaluation [11]. A simplified schematic of
the compartmental model is as shown in Figure 1 to demonstrate.
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Figure 1: Simplified compartmental model, demonstrating diffusion from a donor/vehicle to a
receptor/target, separated by a series of compartments. Modified from Amarah et al. [11].

Generally speaking, the number of compartments and the partitioning coefficients
defining the transport from one compartment to another, are tuned to match experimental
results in order to develop an accurate model [11], [13], [18]. By assuming a series of
several stacked, well-stirred compartments, the compartmental model reduces the
governing equations to a set of related ordinary differential equations (ODE’s), which can
be solved using a Laplace transform, usually with the requirement that the coefficient
terms in the governing equation are not variable [11], [17]. However, the assumption of
well-stirred compartments necessarily results in a loss of spatial resolution; it is this
simplification of spatial independence that allows the diffusion process to be reduced to
allow the practical solution of the pharmacokinetic process. Consequently, the
compartmental model, though simple, does not provide an adequate modeling paradigm
for the goal of this research which is intended to elaborate on the spatial dispersion of the
compound of interest. Other authors have made the attempt to mitigate the solution of the
full PDE’s using linear approximations and Laplace transforms, given the complexity of
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transcendental Eigen functions in the full diffusion model solution [17]. However, this
work is aimed at addressing the full diffusion model as part of the research goal, and the
methodology will demonstrate this focus.
Interestingly, compartment models have also been extended to model general transport of
a compound from one component within a physiological system to another; that is, rather
than capturing spatial phenomenon in the Cartesian sense, this type of compartmental
model represents the transport between functional units within the anatomy, for example,
organs [13]. However, this type of compartmental model differs significantly from the
research goal, so no further work is conducted to implement such a model into the current
approach at this time.
2.1.2. Partitioning and Adsorption Effects
Recall that the skin can be considered to be a binary-mixture system, containing a
lipophilic phase and a hydrophilic phase [2], [8], [10]. This comes with two major effects
in the transport process that need to be considered as part of the modeling effort.
Consider first the simple case of a solute in a closed, single-phase system. In this case, as
time progresses, the solute will tend to diffuse towards a uniform concentration
throughout this single phase. Contrasting to the multi-phase system, the solute will tend
to arrange preferentially to one of the phases in the system [2]. This preferential
arrangement to a phase within the system is referred to as partitioning, and is usually
modeled in a way that relates the concentration of the solute in one compartment versus
the concentration of the solute in another compartment [2], [10], [19].
Within each compartment, the solute may experience differing diffusion coefficients, and
in some cases, such as a lipophilic solute within the cell membrane, the solute may be
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bound to a component of the compartment altogether [2], [19], [20]. This phenomenon is
referred to as “adsorption” in the general case and suggests differing diffusion
coefficients within each compartment [2], [19]. Adsorption effects are sometimes referred
to as “binding” and “unbinding,” this is where the solute may preferentially arrange to a
compartment in such a way that the compounds diffusion is prevented altogether in one
of the compartments, thereby “binding” the compound locally [2].
To account for the multi-phase effects, one begins with the Fickian approach given in
Equation (3). If this equation tracks the concentration in the unbound compartment, 𝑐,
then a second equation needs to be introduced to track the concentration in the bound
compartment, 𝑐 .
𝜕𝑐
=𝐷 𝛻 𝑐
𝜕𝑡

(4)

The partitioning coefficients, otherwise known as the binding and unbinding rate
coefficients define the rate at which the compound transitions from the unbound
compartment to the bound compartment, and vice versa. The binding and unbinding
process is usually modeled using first-order coupling between the compartments,
normalizing by the compartment volume to account for conservation of mass [15], [20]–
[22]. Thus, the pair of equations appears as follows.
𝜕𝑐
𝑉
= 𝐷𝛻 𝑐 + 𝐾 𝑐
−𝐾 𝑐
𝜕𝑡
𝑉

(5)

𝜕𝑐
𝑉
=𝐷 𝛻 𝑐 + 𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉

(6)

Where:
𝑐, 𝑐 = Unbound and bound compound concentrations, [𝑚𝑔/𝑚𝐿]
𝐷, 𝐷 = Unbound and bound diffusion coefficients, [𝑐𝑚 /𝑠]
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𝑉 , 𝑉 = Volumes of tissue and blood compartments, [𝑚𝐿]
𝐾 ,𝐾

= Binding and unbinding rate coefficients, [1/𝑠]

Given that in the bound compartment, the diffusion coefficient, 𝐷 , is effectively zero,
the governing equations given in (5) and (6) can be recast for simplicity as,
𝜕𝑐
𝑉
= 𝐷𝛻 𝑐 + 𝐾 𝑐
−𝐾 𝑐
𝜕𝑡
𝑉

(7)

𝜕𝑐
𝑉
= 𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉

(8)

A simple example of the partitioning and binding can be given in the instance of a
lipophilic compound diffusing through the skin. Partitioning would refer to this lipophilic
compound tending towards cell membranes in the skin. Adsorption would refer to the fact
that once the lipophilic compound adheres to the cell membrane, the compound is
inhibited from freely diffusing through the dermis, thereby limiting its true rate of
diffusion through the dermis.
2.1.3. Elimination Effects
Elimination effects represent the metabolic activity of the solute present in the dermis, as
well as the body’s ability to clear the solute from the tissue, given how well perfused the
dermis is by the capillary system [2], [8], [9]. These effects are typically modeled using
first-order mechanics, behaving as a sort of sink by which the compound is removed from
the domain [2], [10], [15], [16], [23]. In addition to the typical first-order model, there
also exists the Michaelis-Menten model which describes the enzymatic metabolism of a
substrate. This model, if abstracted to the pharmacokinetic problem, would appears as
something like the below equation [24]–[26]:
𝜕𝑐
=𝑉
𝜕𝑡

𝑐
𝐾 +𝑐

(9)
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Where:
𝑐 = Substrate concentration, [𝑚𝑔/𝑚𝐿]
𝑉

= Maximum elimination rate, [𝑚𝑔/𝑚𝐿 ∙ 𝑠]

𝐾 = Michaelis-Menten Constant, [𝑚𝑔/𝑚𝐿]
One notes that the Michaelis-Menten constant acts as a pseudo-equilibrium point, where
model predicts first-order kinetics at low substrate concentrations, 𝑐 ≪ 𝐾 , and zeroorder kinetics at high concentrations, 𝑐 ≫ 𝐾 . This captures the first-order behavior seen
in elimination processes but also reflects the saturation of enzymatic metabolism; where
at high concentrations, the metabolic process is rate-limited by the concentration of the
available enzyme, accounted for within the maximum elimination rate constant, 𝑉
[24]–[26]. However, Michaelis-Menten kinetics are almost exclusively applied to
substrate metabolism through enzymatic reactions. Elimination effects in the dermis are a
consequence of behavior beyond just enzymatic metabolism and there is little literature
which supports the sole application of the Michaelis-Menten model to the
pharmacokinetic modeling paradigm, rather, a paper by Lipscomb and Poet concluded
that TDDD applications typically experience concentrations well below the MichaelisMenten Constant, and so the metabolic behavior would follow first-order kinetics [27].
Thus, the Michaelis-Menten model, which might truly be the more holistic approach to
elimination modeling, is foregone in favor of the first-order elimination model, which is
widely applied to the pharmacokinetic problem [2], [10], [15], [21], [28].
Several works have elaborated on whether elimination effects are important to consider in
the modeling strategy, and all cases, save for a confounding conclusion by Al-Qallaf et
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al. in [15], suggest that elimination effects are essential to the modeling paradigm for
relevance to observed behavior [13], [16], [17], [29].
Again, elimination effects in both dermal compartments are implemented using firstorder kinetics; Equations (7) and (8) are expanded by adding a sink term, such that:
𝜕𝑐
𝑉
= 𝐷𝛻 𝑐 + 𝐾 𝑐
−𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉
𝜕𝑐
𝑉
= 𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉

−𝐾 𝑐

(10)

(11)

Where:
𝐾 = Metabolic rate coefficient, [1/𝑠]
𝐾 = Elimination rate coefficient, [1/𝑠]
The above equations will serve as the basis upon which the meshless modeling method
will be implemented.
2.1.1. Modeling Considerations
Before venturing down the path of developing a numerical model, there are also some
general assumptions with regards to the modeling considerations of the pharmacokinetic
process. First and foremost, the stratum corneum, the most external layer of the skin is
generally perceived as an insulative layer of the skin, inhibiting the diffusive process in
the case of pharmacokinetics [1], [10], [30]. This is a very common assumption, as one of
the physiological purposes of the integumentary system, particularly in the case of the
stratum corneum, is to provide a barrier between the body and the outside world: keeping
bacteria, toxins and other harmful products outside, while retaining moisture, preventing
physical harm to soft tissue, and regulating temperature [8], [9]. Potentially, the stratum
corneum can be modeled as having an incredibly low diffusive coefficient, although this
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work is aimed at bypassing the barrier of the stratum corneum by using microneedles,
which effectively deliver the compound beyond the stratum corneum [1], [15], [30].
Additionally, the pharmacokinetic model treats the interface of the dermis with the
capillary bed as a perfect sink, as the capillary bed is incredibly vascular, and materials
that reach the capillary bed are transported away by the circulatory system rather quickly
[3], [8], [9]. Theoretically, the compound escapes the dermal domain via capillary
clearance and enters the bloodstream. Thus, the blood concentration of the compound can
be tracked, as the compound will accumulate in the blood until it is cleared by other
systems in the body, such as the hepatic system. However, as the concentrations modeled
typically tend to be quite low, blood concentrations of the compound are small enough to
be considered negligible, leading to the approximation of the perfect sink at the capillary
interface.
2.2. Meshless Method
Mesh generation and mesh refinement are critical and resource-intensive problems
associated with conventional numerical techniques, such as the finite difference method
(FDM), finite element method (FEM) and finite volume methods (FVM) [31]–[37]. As a
consequence of its criticality to achieving a stable, accurate and efficient solution, the
meshing effort “… has steadily evolved into a discipline in its own right… .” [31].
Entire methods have since been developed to mitigate the overhead involved with the
meshing process. For example, boundary element methods (BEM) seek to eliminate
domain meshes by using Green’s identities to produce a boundary integral equation,
which reduces a field or domain problem to only it’s boundary, and whole conferences
are dedicated to the boundary element problem and other mesh-reduction methods [38]–
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[40]. Zhu et al. lists nine different methods that have been developed just to address
element locking in cracked bending problems [41].
Other mesh-free methods, including the meshless method, have also been under
development to reduce the computational effort associated with model preparation and
meshing efforts by implementing global interpolation over non-ordered spatial point
distributions [42]–[45]. The, so-called “meshless method” is a general numerical
framework that leverages radial-basis function (RBF) interpolation to provide a true
meshless modeling method that can be extended to a variety of fields and modeling
paradigms [43], [44], [46]. There are a number of advantages, which will be discussed
later, which make the meshless method particularly well-suited to the pharmacokinetic
(PK) problem: meshless methods have already been well established in heat diffusion and
fluid flow problems, meshless methods are considered to be “memory-minimizing” and
resultantly minimize floating-point operations, globally collocated methods exhibit
exponential or “spectral” convergence, locally collocated meshless methods exhibit super
convergence, and meshless pre-computation techniques can be leveraged for efficiency in
iterative solutions [43], [47]–[54]. The focus of the literature review here will be
dedicated to the fundamentals of the meshless method; how it evolved, what contributes
to its accuracy and various implementation considerations. Conventional numerical
techniques will be touched on briefly to give credibility to the present claim of the
difficulty associated with meshing efforts, however, other mesh reduction strategies, such
as the BEM, will be left to the reader to peruse. Given the flexibility of the meshless
method, the implementation of the dermal transport physics is straightforward and will be
covered in the Methodology section below.
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2.2.1. Conventional Numerical Techniques
Inherently, the numerical representation of any complex domain for field solution
modeling generally results in geometrical imperfections through approximation;
imperfections which cause inaccuracies in solutions sought using conventional numerical
techniques such as FDM, FEM and FVM; a phenomenon that is well-documented in
numerical literature [31], [32], [55].
Hughes provides an example in thin shell analysis, which is “notoriously sensitive” to
geometric imperfections [32]. In this work, Hughes demonstrates a considerable
reduction in the buckling load of a perfect cylindrical shell as a consequence of the
meshing effort which produces a faceted geometry. Hughes demonstrated the effects on
the buckling load from this small example via a plot that is given below in Figure 2.

Figure 2: Variations in buckling load of a cylindrical shell in relation to shell thickness
imperfections caused by finite numerical representation [32].
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Hughes continues describing complications due to meshing, noting the sensitivity of
meshed fluid mechanics solutions to geometrical imperfections; particularly in
compressible aerodynamic solvers due to the generation of spurious entropy layers [32],
[55]. There are other considerations when defining a mesh for a numerical simulation,
such as mesh alignment, which can result in “pathologies” in strain localization studies
[56]. These mesh-sensitive behaviors, where mesh construction, including the element
type and orientation, impacts solution accuracy, is reflected in several papers, including
those written by Hennig et al., Du and Wang, Otogoro et al., and others and is effectively
implied by any works where mesh refinement is conducted [33]–[37], [57], [58].
There are two common ways to refine a mesh in conventional methods: h-refinement and
p-refinement methods [32], [59]. In h-refinement, more elements are used to discretize
the domain, thereby reducing element size which in turn reduces approximation errors
[32], [59], [60]. In p-refinement methods, the polynomial degree of the shape functions
implemented in the method, is increased to achieve higher accuracy, i.e. implementing
quadratic elements over linear elements [32], [59], [60].
Since mesh quality has significant impacts on the results of a numerical analysis,
significant time and effort, and therefore cost, is directed towards generating meshes
well. Hughes estimates that about 80% of overall analysis time in the automotive,
aerospace and maritime industries is devoted to mesh generation; as an example for scale,
that estimates approximately four months to the development of a mesh for a single
vehicle in automotive applications [32].
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2.2.1. Meshless Local Petrov-Galerkin (MLPG) and Spectral Methods
Let us begin by first defining what exactly is meant by the phraseology, “meshless
method,” as this definition may soon be blurred with an overview of its historical
development. When the term “meshless method” is used, reference is made to a class of
numerical techniques for solving differential and integral equations by implement
globally supported trial functions for interpolation over an unstructured and non-ordered
point distribution. This will be contrasted to classical spectral and pseudo-spectral
methods as well as the MLPG method shortly. The desire for “an unstructured and nonordered” point distribution is well justified: in irregular geometries, a regular or
structured point distribution may not be trivial to implement or even possible, which can
evolve into problems similar to the geometry preparation and mesh generation issues
observed in these conventional meshed methods. In cases where a formal definition of a
mesh over the point distribution, but there is an underlying requirement for regularity or
structure to the distribution, the term “mesh-free” will be used, indicating that the method
is not necessarily immune to geometry preparation issues.
Therefore, the theoretical foundation of the meshless method can be defined as an
extension of classical spectral or pseudo-spectral methods and the Meshless local PetrovGalerkin (MLPG) method, described excellently by Boyd, and by Atluri and Shen
respectively [42], [43], [61]. To quote Atluri and Shen, “the MLPG method is a very
general concept whose underlying concept serves as a basis for a large number of
variously named minor variations,” and it is this general concept which can be used in
the formulation of the meshless method.
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The fundamental concept underlying these methods is that some field variable, 𝑐(𝒙), can
be approximated by a series of “basis,” “expansion” or “trial” functions, 𝜒 (𝒙), such that:

𝑐(𝒙) ≈

(12)

𝛼 𝜒 (𝒙)

Where:
𝒙 = General spatial coordinates, in 2D, (𝑥, 𝑦)
𝑐(𝒙) = General field variable, in the PK problem, concentration [𝑚𝑔/𝑚𝐿]
𝛼 = Expansion coefficients
𝜒 (𝒙) = Arbitrary, prescribed expansion functions
The term “meshless” is in the name of MLPG methods; they implement a weak form
approach to integrate this approximation over its domain in order to eliminate the
requirement of a formal mesh; a mesh to which locally supported, typically low-order,
basis functions are implemented on [42]. There are other benefits to these methods
besides the mesh elimination, such as the ability to implement high-order trial functions
which lead to high-order continuous approximations, even approximations that can be
infinitely continuous and differentiable, known as 𝐶

(pronounced, c-infinity)

approximations [42], [51]. Spectral methods do not suffer from the same instabilities
present in other methods and can therefore avoid costly instability mitigation strategies
such as forced damping or imposed energy conservation [61]. Additionally, these spectral
methods are accurate and efficient with regards to a memory management sense; Boyd
indicated that in a three-dimensional simulation, a spectral method can resolve flow to
within 1% accuracy of a second- or fourth-order finite difference method using only 1/8
as many degrees of freedom [61].
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However, there is a major caveat to MLPG methods: they are not all truly meshless. For
example element-free Galerkin method and similar methods, require a background mesh
to perform the integration in the weak form, making these formulations “mesh-free” [42].
These weak form methods are referred to as “non-interpolating” methods by Boyd, which
are juxtaposed to “interpolating” methods, another form of spectral method which
implement a strong-form solution to the differential equation approximation and are more
in line with the meshless method formulation provided in this dissertation [61]. Boyd
gives a so-called “moral principle” that argues in favor of the implementation of
Chebyshev polynomials for use as the basis function in the approximation. This moral
principle is quoted here, as its humor is not lost in its original print, and it is the author’s
hope to provide some comic reprieve to the current reader:
Moral Principle 1:
i)

When in doubt, use Chebyshev polynomials unless the solution is spatially
periodic, in which an ordinary Fourier series is better.

ii)

Unless you are sure another set of basis functions is better, use Chebyshev
polynomials.

iii)

Unless you are really, really sure that another set of basis functions is better,
use Chebyshev polynomials.

As is evidenced from the above quote, Boyd’s work is incredibly refreshing but it is also
an incredibly thorough study on spectral methods. Unfortunately, or perhaps ironically,
these Chebyshev polynomials, and other global orthogonal functions suggested by Boyd,
require a uniform or regular nodal point distribution, rendering these methods to be
“mesh-free.” Again, this mesh-free formulation is in direct contrast to our desire to avoid

23
structured point distributions to the best of our ability [43]. Otherwise, these basis
functions are an excellent choice for approaching a solution as they provide the highorder continuity and differentiability required for strong-form solutions.
2.2.2. Radial-Basis Function Interpolation
The meshless method leverages radial-basis function (RBF) interpolation to meet the
requirements for strong-form collocation methods and provide robustness and accuracy to
the solution method. Coincidentally fitting to spectral methods, these functions found
their origin in interpolation techniques for topographical applications using sparse and
scattered data [62], [63]. Rolland Hardy gives the original definition of the multiquadric
(MQ) RBF in application to biharmonic theory [62]. However, there exists a variety of
RBF’s and for completeness, they are given below.
1. Polyharmonic Splines RBF
𝜒 (𝒙) =

𝑟 (𝒙)
𝑐

(13)

or …
𝜒 (𝒙) =

𝑟 (𝒙)
𝑐

ln

𝑟 (𝒙)
𝑐

(14)

2. Gaussian RBF
𝜒 (𝒙) = 𝑒𝑥𝑝 −

𝑟 (𝒙)
𝑐

(15)

𝑟 (𝒙)
𝑐

+1

(16)

3. Multiquadric RBF

𝜒 (𝒙) =

a. Inverse Multiquadric (𝑛 = 1)
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𝜒 (𝒙) =

𝑟 (𝒙)
𝑐

+1

(17)

b. Direct Multiquadric (𝑛 = 2)

𝜒 (𝒙) =

𝑟 (𝒙)
𝑐

+1

(18)

Where:
𝒙 = General spatial coordinates, in 2D, (𝑥, 𝑦)
𝑟 (𝒙) = Euclidean distance from expansion point, (𝑥 , 𝑦 );
in 2D, 𝑟 (𝒙) =

𝑥−𝑥

+ 𝑦−𝑦

𝑐 = Shape parameter, or shape factor
For a visual representation of their behavior, these RBF’s are graphed over a 2D domain,
with 𝑥 ∈ [−1, 1], and 𝑦 ∈ [−1, 1]. The shape parameter is arbitrarily defined for each
RBF in order to produce a visual representation where the behavior of the RBF is easily
observable.
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Figure 3: Visual representation of several Radial-Basis Functions (RBF’s): (1) Polyharmonic
Spline RBF, (2) Gaussian RBF, (3a) Multiquadric RBF – Inverse Multiquadric (IMQ), (3b)
Multiquadric RBF – Direct Multiquadric (DMQ)

We will note briefly here that the shape factor plays of the RBF is a tunable parameter of
the meshless method and its choice plays a very significant role in the accuracy of the
solution. There will be further discussion on this momentarily, but for now, it will suffice
to show that the shape factor directly affects the flatness or steepness of the RBF. In the
case of the Inverse Multiquadric (IMQ) RBF, as the shape factor increases, the RBF
observably becomes more and more flat, demonstrated below in Figure 4.

26

Figure 4: Inverse Multiquadric RBF demonstrating increased flatness with increasing shape factor

Observing the limit, one notes that as the shape factor increases, it dominates the radial
term forcing the IMQ RBF to 1.
lim
→

1
𝑟 (𝒙)
𝑐

=1
+1

(19)

There are several interesting properties of the MQ RBF when considering its performance
in interpolation application, all of which make them particularly well suited to use as a
basis function in the meshless method [47], [48], [63]. Immediately apparent is that the
IMQ RBF is infinitely continuous and differentiable everywhere, referred to as 𝐶 , even
at their own pole, making them an appealing basis function for spectral methods, as high
orders of continuity are a requirement for strong form solutions. Additionally, RBF’s are
globally supported, requiring a simple Euclidean distance calculation between any two
“arbitrary” locations in the domain. This eliminates the requirement for a regular point
distribution when RBF are used as the interpolating function in spectral methods. All of
these conspire to make RBF’s incredibly well-suited to interpolation, outperforming most
other functions in this effort, with Hardy’s MQ RBF being the outright best performer
across several metrics, including accuracy and ease of implementation [64]–[66]. In fact,
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Franke, in a study comparing interpolating methods on scattered data referred to Hardy’s
MQ RBF method as being the preeminent global method, referring to the method as “…
perhaps the best of all global methods considered,” comparing the method also to a finite
element based method, and other global and local methods [64].
2.2.3. Collocation and Convergence
Madych and Nelson established an error estimate for the RBF interpolation strategy,
however, before diving into this topic, a few words need to be said about collocation.
Collocation is an error minimization method closely tied to interpolation; in spectral
methods, it where the error of the numerical (approximate) solution is zero at a certain set
of points which are equal in number to the expansion coefficients used in the
approximation [61]. So, the approximation given in equation (12) would be exact at each
of the expansion points, (𝑥 , 𝑦 ), given by the basis function, such as the IMQ RBF given
in equation (17). This “collocation method,” where the error is minimized at these
expansion points or “collocation points,” is one of many residual minimization methods,
but, as explained by Boyd, is simple, guaranteed to work, and is in fact the superior
choice if executed correctly [61]. Collocation methods are juxtaposed to the method of
weight residuals (MWR), which serve as the foundation for finite difference, element and
volume methods, and least-squares which distribute the error across the solution domain.
With this in mind, the approximation of the differential equation field solution is
“collocated” at a set of expansion points of our choosing; the differential equation is
exactly satisfied at these points. This allows us to make a small modification to equation
(12) such that,
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𝑐(𝒙) =

𝛼 𝜒 (𝒙)

(20)

Given this requirement that the differential equation is satisfied at these collocation
points, they are also sometimes referred to as “interpolation points,” as the entire field
solution can be interpolated from these points; these collocation points essentially serve
as a way to anchor the solution or interpolation over the domain. Traditionally,
particularly in the case of Chebyshev and Legendre polynomials in spectral methods, this
collocation and equation assembly is performed globally; that is, the influence of every
collocation point in the domain is used for interpolating the solution at any location in the
domain. The implementation of global collocation will be defined mathematically in
Section 3.2.1, but first, a brief discussion on the various collocation strategies and their
respective convergence rates of their approximation error.
Global collocation benefits from exponential or “spectral” convergence rates, which is a
significant improvement over traditional numerical methods which converge at
polynomial or “algebraic” rates [53], [67], [68]. Convergence refers to the interpolation
error of a collocation scheme; that is, an interpolation technique, such as RBF
interpolation, will generate a field solution which differs from the true field solution by
some error or residual, 𝑟(𝒙). Typically, the accuracy of the interpolation is improved by
including more collocation points in the calculation to “anchor” the solution and reduce
the residual. This closely resembles h-refinement of the FEM, where better mesh
resolution increases solution accuracy [68]. Given that a collocation method is
implemented, then the interpolation error of interpolation schemes matches the
approximation error of PDE solution schemes which leverage these interpolating
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techniques [69]. This behavior, the reduction in approximation error with various
refinement strategies, is the essence of what is intended by “convergence.”
Again, the finite element method and similar methods experience algebraic convergence
rates, meaning that the approximation error, 𝜀, converges on the order of 𝑂(ℎ ), where:
ℎ = Mesh size, i.e. 1D problem with domain, length 𝐿, with 𝑚 elements, ℎ = 𝐿/𝑚
𝑛 = Polynomial order of FE basis functions
Of course, in order to increase the polynomial order of the basis functions, more nodes
which define the field solution need to be added, resulting in more unknowns and
nontrivial increased solution complexity, and may even introduce instability into the
solution [53], [61]. The polynomial order of the basis functions is closely tied to the
concepts of isoparametric, superparametric, and subparametric elements in FEM and has
a practical limit with regards to how high an order can be attained before being surpassed
by spectral methods [61], [70].
Globally collocated meshless methods exhibit spectral convergence, meaning that the
error, 𝜀, converges on the order of 𝑂 𝜆
𝜀 converges on the order of 𝑂 𝑒 𝜆

/

/

; particularly for MQ-RBF meshless methods,

, where:

ℎ = Mesh size, i.e. 1D problem with domain, length 𝐿, with 𝑚 elements, ℎ = 𝐿/𝑚
𝑐 = RBF Shape Factor
𝜆 = Constant where 𝜆 ∈ (0, 1)
𝑎 = Some positive constant
As FEM methods have h-refinement and p-refinement, the global collocation meshless
method experiences a similar refinement strategy, as indicated by the order of the
approximation error, where the shape factor, 𝑐, can be tuned to minimize the
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approximation error. There is no formal name for this strategy, but is referred to as the cscheme by Chen [68]. The c-scheme technically incurs no further computational cost to
implement. Additionally, as theorized by Madych, as the shape factor tends towards
infinity, the approximation error will tend to zero, which is an incredible benefit [71]!
Unfortunately, this is not actually realizable given the requirement for a matrix inversion
for the solution and limits on numerical precision [68], [72]. What is usually observed is
that the accuracy of the solution will improve as the shape factor increase, up until a point
where the solution matrix becomes ill-conditioned, and the solution breaks down, a
behavior that is predicted by Shaback’s “uncertainty principle” [51], [67], [68], [73]. This
is a well-documented problem, and many solutions have been proposed to address the
issue, such as extended precision computing (i.e., quadruple precision versus double
precision), randomly perturbing node positions, various pre-conditioning schemes,
domain decomposition, truncated basis, and more [43], [51], [68], [71], [73]–[77].
Interestingly, Cheng finds a way to leverage this behavior to maximize the accuracy of
the global collocation solution [67]. As the shape factor can be increased “for free,”
Cheng uses an optimization technique to maximize the shape factor before the solution
approaches ill-conditioning, guaranteeing the most optimal solution realizable given
machine precision limits [67].
There are several methods proposed to address the ill-conditioning of the global
collocation scheme, some of which with obvious shortcomings. For example, quadruple
precision computing sounds very attractive and if the issue is machine representation
leading to degenerate ranking in a matrix, why not attack the problem directly and just
extend the precision to increase accuracy? The obvious answer is that quadruple precision
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hardware is extremely uncommon and the “double-double precision” approach is not
trivial and incurs a time penalty for each extended precision computation [78]. Another
example is domain decomposition; breaking the domain down into several smaller
“chunks” allows for smaller solution matrices, thereby mitigating the onset of illconditioning. However, domain decomposition necessitates artificial interfaces between
sub-domains with an interfacial boundary condition imposed at these interfaces; these
interfacial boundary conditions require an iterative solution at each time step in order to
converge on a true time-accurate solution [43].
One notices that many of the mitigation strategies noted above actually involve some
form of breaking the large, global collocation matrix into smaller matrices for solution. In
fact, the prevailing solution method, local collocation results in a very similar strategy,
but does not require dividing the domain into subdomains and therefore mitigates the
additional effort associated with domain decomposition, or the decomposition and
overlap required in multizone methods [54], [76]. Local collocation creates topologies of
influence around the data center of interest, and constructs the collocation using only
points within this topology [43], [46], [79]. Full details on how local collocation is
implemented will be reserved for the methodology section, but it is worth noting that the
local collocation meshless method does not suffer from ill-conditioning to the same
degree as the global collocation method while still offering many benefits of the global
collocation method [43], [46]. Interestingly, there is very little literature that has looked
into the convergence property of locally collocated methods; but by formulation, it is
guaranteed that the local collocation meshless method loses spectral convergence as it
gives up the global collocation to mitigate this ill-conditioning. Unlike work defining the
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convergence of the FEM and globally collocated MQ methods, there is no analytical
derivation of the error convergence of the locally collocated method. There is, however,
one paper which estimates the convergence behavior of the local collocation meshless
method by using numerical experiments; according to Ding et al., the error, 𝜀, converges
on the order of 𝑂((ℎ/𝑐) ), where [54]:
ℎ = Mesh size, i.e. 1D problem with domain, length 𝐿, with 𝑚 elements, ℎ = 𝐿/𝑚
𝑐 = RBF Shape Factor
𝑛 = Positive constant, determined by number of collocation points in the topology
This seems to converge following a power law relationship similar to meshed methods,
which doesn’t appear to be any improvement. However, Ding demonstrated that the
convergence of the locally collocated method is actually superconvergent, indicating that
the power at which the error converges is much higher than in meshed methods [54].
What does this mean practically? First, recall that the algebraic convergence rate of
meshes methods is on the order of 𝑂(ℎ ), where the exponent is equivalent to the power
of the basis functions. These basis functions are typically linear or quadratic, as higher
orders can introduce a “snaking” instability of the solution, but with some effort and
monotonicity constraints, can be pushed to cubic orders [51], [59], [68], [80].
Superconvergence would refer to any method where the convergence order exceeds the
polynomial order of the basis functions, and Ding consistently demonstrates the
convergence order of the local collocation meshless method to exceed cubic rates using a
method that is splendidly simple [54]. To reiterate, the positive constant in the exponent,
𝑛, is based on the number of collocation points within the topology of influence, 𝑛 , and
the inclusion of additional collocation points within the topology is trivially simple, as
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will be demonstrated later, to the point where it can be fully automated [54].
Additionally, the presence of the shape factor in the convergence order is indicative that
c-refinement is still a viable strategy for locally collocated methods. Thus, local
collocation provides an incredibly convenient and attractive approach to achieving
accurate solutions by leveraging high convergence rates without the issues of illconditioning.
2.3. Summary
The pharmacokinetic problem set is one of relative complexity with a variety of
multiphysics phenomenon to consider, including diffusive effects, elimination effects and
adsorption and partitioning effects associated with the multiple phases of the dermis.
Though the diffusive effects can be modeled using a compartmental approach, it is
preferred to take a true diffusive approach, as the goal of this work is to elaborate on
localized concentrations of any compound in addition to the systemic concentrations.
Given this complexity, a numerical approach is sought to the solution of the governing
equations to arrive at a field distribution of the compound concentration in the dermis.
However, this is not a trivial effort; given the scale of the domain and the requirement of
extensibility to inverse methods, a robust and efficient numerical method is required.
Traditional numerical methods are fraught with errors due to meshing, particularly when
problems have complex geometries or physics. Thus, the desire to implement a meshless
method, which eliminates the complexities and consequences of a mesh. This allows
more efficient modeling strategies and allows a more robust automation of inverse
problems, by avoiding mesh instabilities. The global collocation meshless method,
particularly when leveraging multiquadric radial-basis functions, solves many of the
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issues expected from traditional modeling endeavors, particularly in this application.
However, global collocation suffers from ill-conditioning as the shape factor increases, a
common technique for refining the accuracy of the solution. This problem is not entirely
trivial, so alternatives have been studied. The most promising “fix” for the illconditioning problem is to implement local collocation. Local collocation breaks the
single, large, fully-populated and ill-conditioned solution matrix into several, smaller,
full-rank matrices. Local collocation sacrifices spectral convergence to mitigate the illconditioning problem, however, the method still benefits from super convergence,
making it significantly more efficient than conventional numerical methods, and many
other advantages, such as ease of implementation and a precomputation strategy that will
be discussed later. Given these advantages, the LCMM is the method of choice in
solution of the pharmacokinetic problem. Continuing through this dissertation, some
details of the globally collocated version of the meshless method will be presented to
contribute to the readers understanding of the LCMM but realize that it is the locally
collocated version that will find application to the problem set at hand.
2.4. Research Contribution
There are not very many applications of numerical techniques to the solution of the full
diffusive form of the pharmacokinetic equations governing transdermal drug delivery.
The first effort is given by Tojo in 1987, where a FD derived mesh is used to decompose
the governing PDE’s spatially into a set of ODE’s, and then applying the Runge-KuttaGill algorithm to the solution of the ODE’s to approximate the PDE solution in one
spatial dimension [28]. Another such effort is given by Al-Qallaf where a onedimensional FD approach is taken, but there are many facets of this work which are either
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unexplained or in need of further validation [15]. Xiao gives a 2D FEM solution to water
diffusion through the stratum corneum but does not account for many of the effects
described above, such as elimination or partitioning [81]. Likewise, Barbero performs a
2D FEM solution to the problem with partitioning but without metabolic effects [19].
Thus, this work aims to provide one of the few multi-dimensional numerical frameworks
to solving the full set of PK equations in an effort to elaborate on concentration profiles.
This is the first work to leverage the highly efficient localized collocation meshless
method to approach such a solution, thereby providing a practical means to study iterative
design and optimization problems. Furthermore, one of the few analytical solutions of the
PK problem is developed to validate the numerical technique and ensure its relevance to
the problem. It is the hope that this work can provide a tool to aid and advance clinical
research in the field of transdermal drug delivery by complimenting the empirical body of
knowledge in the medical community to develop useful drug delivery systems.
Additionally, there are so few validations of locally collocated meshless methods in
literature. Given that an analytical solution is derived for this PK problem set, this work
is uniquely aimed at expanding the literature on validation and convergence studies of
localized meshless methods and may serve as the basis for future research in establishing
a true convergence rate for these methods.
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3. Methodology
A short roadmap will be provided to give an overview of the work included in this
dissertation, to see how the various sections of methodology are tied together within the
big picture of the numerical framework provided.
3.1. Research Approach
First, global collocation will be explained in the context of meshless methods. This is the
traditional approach taken with meshless methods and helps lay a foundation for
understanding the local collocation approach, or at the very least, gives some context
behind collocation and serves as a counter example for local collocation.
At this point, local collocation will be explained. This should appear as a simple exercise
after having global collocation explained. The local collocation method will be shown in
application to the set of equations governing TDDD, with a demonstration of how
transience is addressed, with a few comments on how to improve the local collocation.
With the numerical method described, the analytical solution will be given to provide a
validation of the LCMM applied to the pharmacokinetic equation. Additionally, a few
words will be said with regards to how this analytical solution is used to quantify the
convergence of the LCMM.
Next, a brief sensitivity study will be conducted with a two-fold purpose; primarily, the
sensitivity study will serve as a useful precursor to understanding the inverse problem to
come, and but will also demonstrate the robustness of the LCMM. Ideally, the solution
method should not be extremely sensitive to input parameters, and this brief study sets
out to demonstrate that fact.
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After having validated the LCMM with application to the pharmacokinetic governing
equations, a simple inverse problem of parameter identification (PID) will be evaluated.
This inverse problem will be used to explore a way in which the diffusion coefficient of a
compound can be derived, demonstrating how in silico studies can be used in conjunction
with empirical data to characterize a novel compound.
Finally, a few words will be said on the LCMM implementation of the Volume-of-Fluid
(VOF) method, as this will provide a way to improve the LCMM’s performance in more
complicated inverse problems. Although there are no direct applications of the VOF
method to the pharmacokinetic problem presented in this work, the VOF method poses a
potential solution to problems of domain reconstruction that are expected in inverse
geometry problems, such as the optimization of the shape of a microneedle array.
3.2. Meshless Method
3.2.1. Global Collocation
Reiterating the equations which govern the pharmacokinetic process:
𝜕𝑐
𝑉
= 𝐷𝛻 𝑐 + 𝐾 𝑐
−𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉
𝜕𝑐
𝑉
= 𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉

−𝐾 𝑐

(21)

(22)

Consistent with the formulation given in the literature review and described in equation
(20), the foundation of the collocation meshless method is that any field variable, here,
the compound concentration, 𝑐(𝒙), can be approximated by a series of basis functions,
𝜒 (𝒙), such that:

𝑐(𝒙) =

𝛼 𝜒 (𝒙)

(23)
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Where:
𝒙 = General spatial coordinates, in 2D, (𝑥, 𝑦)
𝑐(𝒙) = General field variable, in the PK problem, concentration [𝑚𝑔/𝑚𝐿]
𝛼 = Expansion coefficients
𝜒 (𝒙) = Arbitrary, prescribed expansion functions
To arrive at the solution, a system of equations based in equation (23) needs to be
assembled over the domain. Traditionally, particularly in the case of Chebyshev and
Legendre polynomials in spectral methods, this collocation and equation assembly is
performed globally; that is, the influence of every collocation point in the domain is used
for interpolating the solution at any location in the domain. To describe this visually,
assume some generic domain, Ω, circumscribed by boundary, Γ, with collocation points
scattered arbitrarily within the domain and on the boundary. For book-keeping purposes,
assume that there are 𝑁𝐼 collocation points within the domain, and 𝑁𝐵 collocation points
on the boundary, summing to 𝑁 collocation points in total.

Figure 5: Generic domain, Ω, with boundary, Γ, populated with N collocation points
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When forming the interpolation, global collocation would collect the influence of every
expansion point in the domain on the point of which we are interested. This would appear
as such:

Figure 6: Demonstration of global collocation method used to generate the field interpolation
equation on a point.

Notice that at point, 𝑋, the influence of the point itself is included in the collocation. This
collocation is repeated at every node in the domain, resulting in 𝑁𝐼 equations, creating a
square system of equations for calculating the concentration at interior points.
3.2.1. Local Collocation
The localized form of collocation follows very closely the concept of global collocation.
However, the distinction between that two is that instead of accumulating the influence of
every point in the domain and assembling this system into one large matrix of questions,
there is a topology of influence around the node of interest and only the 𝑁𝐹 points within
this topology are used in assembling the interpolation at the node. Demonstrating
visually, this appears as:
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Figure 7: Demonstration of local collocation method used to generate the field interpolation
equation on a point.

Note that a topology of influence is constructed for each internal node in the domain. The
many localized topologies allow us to interpolate the field variable using a series of basis
functions but limits the influence to only being collected from a smaller number of
neighboring nodes as opposed to the entire domain, preventing rank degeneracy and illconditioning. Additionally, series expansion can be augmented using 𝑁𝑃 polynomials in
order to ensure the exact retrieval of constant and linear fields, and to eliminate
stagnation error in the field approximation [82], [83]. This augmentation appears as:
𝑐(𝒙) =

𝛼 𝜒 (𝒙) +

𝛼

𝑃 (𝒙)

Where:
𝜒 (𝒙) = Arbitrary, prescribed expansion functions, here the IMQ-RBF
𝑃 (𝒙) = Polynomial function to augment the radial-basis expansion function
𝛼 = Expansion coefficients

(24)
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Here, the basis function is defined using the inverse multiquadric radial-basis function
(IMQ RBF), as this RBF is non-singular at its collocation point, where the IMQ RBF is
given in equation (17) as:
𝜒 (𝒙) =

1
𝑟 (𝒙)
𝑐

(25)

+1

As there is an analytical form of the basis function and polynomial term in hand, field
derivatives of the concentration can be approximated by taking the analytical derivative
of the RBF and polynomial functions, rather than by using a finite-differencing
approximation of the field derivate. For example, in the first derivative in the local xcoordinate:
𝜕𝑐(𝒙)
=
𝜕𝑥

𝛼

𝜕𝜒 (𝒙)
+
𝜕𝑥

𝛼

𝜕𝑃 (𝒙)
𝜕𝑥

(26)

This same process applies to higher order derivates, such as the Laplacian:
𝛻 𝑐(𝒙) =

𝛼 𝛻 𝜒 (𝒙) +

𝛼

𝛻 𝑃 (𝒙)

(27)

Reflecting on equation (24), all terms of the equation are known, with the exception of
the expansion coefficients, 𝛼 . The solution of these coefficients will be addressed
shortly, after collocation is elaborated on more fully.
It is important to recall here that the approximation error of the LCMM converges on the
order of 𝑂((ℎ/𝑐) ), meaning that the shape factor of the RBFs has a rather significant
impact on the solution accuracy, with larger shape factors resulting in more accurate
solutions. Thus, the shape factor can be optimized in order to maximize the obtainable
accuracy of the solution. To that end, Cheng et al. discussed and performed this so called
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“c-refinement” on a globally collocated method, optimizing the shape factor to arrive at
the most accurate solution realizable given machine precision limits [67]. In the same
fashion as the method presented by Cheng, the shape factor is optimized over each
topology, by calculating the ratio of the matrix’s singular values, in order to maximize the
accuracy of the solution as a whole.
3.2.2. Meshless Method – Time Integration
To address the transient aspect of the solution, a first-order forward differencing
approximation of the time derivative is posed to formulate an explicit integration scheme.
This is demonstrated for both the unbound and bound concentration equations:
𝑐(

)

= 𝑐(

𝑐

(

)

)

+ ∆𝑡 𝐷𝛻 𝑐 (

=𝑐

( )

+ ∆𝑡

)

+ 𝐾 𝑐

𝐾 𝑐(

)

( )𝑉

𝑉

− 𝐾 𝑐(

𝑉
(
−𝐾 𝑐
𝑉

)

)

− 𝐾 𝑐(

−𝐾 𝑐

)

( )

(28)

(29)

Where:
𝑐(

)

𝑐(
𝑐

( )

𝑐

(

= Field solution of unbound concentration at current time step [𝑚𝑔/𝑚𝐿]
)

= Field solution of unbound concentration at next time step [𝑚𝑔/𝑚𝐿]

= Field solution of bound concentration at current time step [𝑚𝑔/𝑚𝐿]
)

= Field solution of bound concentration at next time step [𝑚𝑔/𝑚𝐿]

𝑘 = Denotes the current time level
∆𝑡 = Size of the solution time step
Of course, this form necessitates that some initial condition is prescribed for the domain,
which is a simple enough exercise. With the initial condition prescribed, the field solution
for the next time step is calculated using this time-integration scheme. Recall that for the
field variable expansion, the expansion coefficients, 𝛼 , are still unknown. However, with
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the estimation of the field values at the next time-step using the time-integration scheme,
one can construct the collocation matrix, [𝐶], to calculate these expansion coefficients by
using the vector-matrix form of the series expansion given in equation (24):
{𝑐} = [𝐶]{𝛼}

(30)

Where:
{𝑐} = Vector of unbound concentrations at nodes for the current time step
[𝐶] = Collocation matrix
{𝛼} = Vector of expansion coefficients, 𝛼 , corresponding to expansion functions
We will demonstrate using the unbound concentration, 𝑐(𝒙), and refer to the vector of
unbound concentrations at internal nodes as {𝑐}, where:
𝑐(𝒙 )
⋮
⎛
⎞
)
{𝑐} = ⎜𝑐(𝒙 ⎟
⎜ 0 ⎟
⋮
⎝ 0 ⎠

(31)

Then, the collocation matrix, [𝐶], is defined as:
𝜒 (𝒙 )
⎡
⋮
⎢
𝜒 (𝒙 )
[𝐶] = ⎢
⎢ 𝑃 (𝒙 )
⋮
⎢
𝑃
(𝒙
)
⎣

⋯
⋱
⋯
⋯
⋱
⋯

𝜒

(𝒙 )
𝑃 (𝒙 ) ⋯ 𝑃 (𝒙 )
⎤
⋮
⋮
⋱
⋮
⎥
𝜒 (𝒙 )
𝑃 (𝒙 ) ⋯ 𝑃 (𝒙 )⎥
𝑃 (𝒙 )
0
⋯
0 ⎥
⋮
⋮
⋱
⋮ ⎥
𝑃 (𝒙 )
0
⋯
0 ⎦

(32)

With the corresponding expansion coefficients, {𝛼}, defined as:
{𝛼} =

𝛼
⋮
𝛼

(33)

Finally, these expansion coefficients can be calculated where,
{𝛼} = [𝐶] {𝑐}

(34)
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3.2.3. Derivative Precomputation
One of the major benefits of the LCMM formulation using RBFs is the precomputation of
field derivative operators. Recall that derivative operators can be defined by analytically
deriving the series expansion; then for any linear derivative operator, ℒ, at some
collocation point, 𝒙 :
ℒ𝑐(𝒙 ) =

𝛼 ℒ𝜒 (𝒙 ) +

𝛼

ℒ𝑃 (𝒙 )

(35)

This can be rewritten in matrix form, as:
ℒ𝑐 = {ℒ } {𝛼} → ℒ𝑐 = {ℒ } [𝐶] {𝑐}

(36)

ℒ𝜒 (𝒙 )
⋮
⎛
⎞
ℒ𝜒 (𝒙 )
⎟
{ℒ } = ⎜
⎜ ℒ𝑃 (𝒙 ) ⎟
⋮
⎝ℒ𝑃 (𝒙 )⎠

(37)

Where:

Notice that the vector defining the linear differential operator, ℒ , is based solely on the
expansion functions within the topology. This means that for any derivative operator, at
all time-steps, the vector derivative operator, ℒ , remains the same and can therefore be
calculated at some initial pre-processing step when the topologies are defined. From this
point onwards, all future derivative calculations are a simple vector-vector multiplication
of the field variable of interest and derivative operator vector. This can be leveraged quite
powerfully in inverse problems, as this derivative operator is still valid across multiple
solutions so long as the topologies do not change from one solution to the next.
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3.2.4. Boundary Equations
With the internal solution obtained, attention can be turned towards the boundary points.
While internal concentrations are derived from the governing equations, for boundary
nodes, the concentration is imposed by a generalized set of boundary equations for the
concentration, 𝑐(𝒙), as given by:
𝛽 𝑐(𝒙)| + 𝛽

𝜕𝑐
(𝒙)
𝜕𝑛

(38)

=𝛽

The coefficients, 𝛽 , 𝛽 , 𝛽 , are known a priori and are used to impose, first, the type of
boundary condition, either Dirichlet, Neumann, or Robin and second, constrains the value
at each boundary node. This generalized boundary condition allows a uniform method in
which all forms of boundary conditions are handled across all nodes, thereby simplifying
the calculation of boundary values. In each type of boundary condition, the coefficients
are as follows:
1. Dirichlet, or First-kind Boundary Condition:
𝑐|

= 𝑐̂

∴ 𝛽 = 1, 𝛽 = 0, 𝛽 = 𝑐̂

(39)

2. Neumann, or Second-kind Boundary Condition:
𝐷

𝜕𝑐
𝜕𝑛

= −𝐽

∴ 𝛽 = 0, 𝛽 = 𝐷, 𝛽 = −𝐽

(40)

3. Robin, or Third-kind Boundary Condition:
𝑐| +

𝐷 𝜕𝑐
ℎ 𝜕𝑛

= 𝑐̂

∴ 𝛽 = 1, 𝛽 =

𝐷
, 𝛽 = 𝑐̂
ℎ

(41)

Similar to the interior collocation, the boundary conditions can be collocated at the
boundary nodes, and by utilizing the series expansion, can be reduced to a square, linear
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system of equations to derive the expansion coefficients in the following manner. Starting
with the series expansion of equation (38):

𝛽

𝛼 𝜒 (𝒙)

+𝛽

𝛼

𝜕𝜒 (𝒙)
𝜕𝑛

=𝛽

(42)

Reordering the coefficients for clarity in the next step yields:

𝛼 𝛽 𝜒 (𝑥)

+

𝛼𝛽

𝜕𝜒 (𝒙)
𝜕𝑛

=𝛽

(43)

Then, like terms can be collected:

𝛼 𝛽 𝜒 (𝑥) + 𝛽

𝜕𝜒 (𝒙)
𝜕𝑛

=𝛽

(44)

Arriving at the simplified form of the system:

𝛼 𝜓 (𝒙)

(45)

=𝛽

Again, where:
𝜓 (𝒙) = 𝛽 𝜒 (𝑥) + 𝛽

𝜕𝜒 (𝒙)
𝜕𝑛

(46)

This system can be combined with the expanded equations from the internal nodes,
leading to the square, linear algebraic vector-matrix relation:
{𝛽} = [𝐴]{𝛼}

(47)

Where:
{𝛽} =

[𝐴] =

𝛽
0
𝜓 (𝒙)
𝑐 (𝒙)

(48)
(49)
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Thereby arriving at the expansion coefficients by inverting the relationship to arrive at:
(50)

{𝛼} = [𝐴] {𝛽}
3.3. Analytical Validation and Convergence

Though a method may appear sound theoretically, how does one know it works? The
validation approach of a model is often as important as the development of the model
itself, and here, that effort is defined. Of primary importance is the derivation of the
analytical solution to the governing equations. With that in hand, there is needed some
method by which the numerical solution can be compared to the analytical solution, to
derive some sense of its accuracy. Finally, as an analytical solution will be at hand for the
governing equations, there is a convenient method by which the convergence behavior of
the numerical method can be quantified. Initially, a validation of the numerical method
was sought using existing literature, however, those papers that were published in a
similar field did not provide enough information to properly serve as a point of
validation, thereby motivating the analytical solution.
3.3.1. Analytical Solution
The analytical solution begins with the governing equations, as given in equations (10)
and (11), reproduced here for clarity.
𝜕𝑐
𝑉
= 𝐷𝛻 𝑐 + 𝐾 𝑐
−𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉
𝜕𝑐
𝑉
= 𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉

−𝐾 𝑐

(51)

(52)

In order to arrive at a practical analytical solution, several assumptions and limitations
need to be made with respect to the solution domain. First, the solution is sought over a
one-dimensional domain of length 𝐿, serving as a depth-wise solution of the compound’s
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diffusion. In this case, there are then two boundaries to our domain; the first, at the
interface between the needle and the dermis, 𝑥 = 𝐿, treated as a first-kind boundary
condition held at the administered concentration of the needle, 𝑐|

= 𝑐̂

, and

second, at the interface between the dermis and the capillary bed, 𝑥 = 0, where the
boundary serves as a perfect sink, also a first-kind boundary with a zero concentration,
𝑐|

= 0 𝑚𝑔/𝑚𝐿, [10], [15]. It is assumed that, initially, there dermis is clear of the

existing compound, and therefore the initial concentration in the dermis is zero, leading
to initial conditions in the unbound and bound compartments, 𝑐(𝑥, 0) = 0 𝑚𝑔/𝑚𝐿 and
𝑐 (𝑥, 0) = 0 𝑚𝑔/𝑚𝐿. These assumptions can be modified, but having the assumption is
a necessity to constrain the PDE to arrive at a proper analytical solution.
Considering the one-dimensional solution domain, the Laplacian reduces to a secondorder derivative in the one spatial direction, yielding the following set of equations.
𝜕𝑐
𝜕 𝑐
𝑉
=𝐷
+ 𝐾 𝑐
−𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝜕𝑥
𝑉
𝜕𝑐
𝑉
= 𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉

−𝐾 𝑐

(53)

(54)

For compactness, like terms are collected:
𝜕𝑐
𝜕 𝑐
=𝐷
+𝐾 𝑐+𝐾 𝑐
𝜕𝑡
𝜕𝑥

(55)

𝜕𝑐
=𝐾 𝑐 +𝐾 𝑐
𝜕𝑡

(56)

𝐾 = −𝐾 − 𝐾

(57)

Where:

𝐾 =𝐾

𝑉
𝑉

(58)
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(59)

𝐾 = −𝐾 − 𝐾
𝑉
𝑉

𝐾 =𝐾

(60)

In characterizing the solution, it is important to note that the constants, 𝐾 and 𝐾 are
always negative, whereas the constants 𝐾

and 𝐾

are always positive for any

physiologically meaningful model.
To advance, observe that equation (56) is dependent only on the first-order derivative in
time of the bound concentration, 𝑐 . This derivative then can be effectively taken as a
total derivative, allowing (56) to be solved with an integrating factor. Thus, the
concentration of the compound in the bound compartment can be represented as a
function purely of time and the unbound concentration, where:
𝑐 =𝑒

𝐾

𝑒

(61)

𝑐 𝑑𝑡

Substituting (61) back into equation (55) yields the following integro-differential
equation:
𝜕𝑐
𝜕 𝑐
=𝐷
+𝐾 𝑐+𝐾 𝐾 𝑒
𝜕𝑡
𝜕𝑥

𝑒

𝑐 𝑑𝑡

(62)

To arrive at a particular solution, the boundary and initial conditions are imposed in
accordance with the assumptions stated prior. Given that there is a non-homogenous
boundary condition at the tip of the microneedle, the solution of the integro-differential
equation can by the principle of superposition. Using this approach, the unbound
concentration consists of both a steady component, 𝑐 (𝑥), as well as a transient
component, 𝑐 (𝑥, 𝑡), where:
𝑐(𝑥, 𝑡) = 𝑐 (𝑥) + 𝑐 (𝑥, 𝑡)

(63)
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This formulation then necessitates the solution of two sub-problems: first, the steady
component which carries information imposed by the non-homogenous boundary
condition, and second, a transient component defined by a purely homogenous rendition
of the initial field problem. The steady problem implies the existence of a timeindependent component of the field variable. The application of this superposition
assumption renders the following equation and boundary conditions defining the steady
component of the field solution:
𝜕𝑐
𝜕 𝑐
=𝐷
+𝐾 𝑐 +𝐾 𝐾 𝑒
𝜕𝑡
𝜕𝑥

𝑒

𝑐 𝑑𝑡

(64)
(65)

𝑐 (0) = 0

(66)

𝑐 (𝐿) = 𝑐

Likewise, the transient component is then defined by the following equations, initial
condition and boundary conditions, as derived from the governing equations:
𝜕𝑐
𝜕 𝑐
=𝐷
+𝐾 𝑐 +𝐾 𝐾 𝑒
𝜕𝑡
𝜕𝑥

𝑒

𝑐 𝑑𝑡

(67)

𝑐 (𝑥, 0) + 𝑐 (𝑥) = 0

(68)

𝑐 (0, 𝑡) = 0

(69)

𝑐 (𝐿, 𝑡) = 0

(70)

Additionally, it is important to note that the initial concentration in the bound
compartment is zero.
Steady Solution
In addressing the steady solution, the assumption of time-independence of the steady
unbound concentration results in the following simplifications:
𝜕𝑐
=0
𝜕𝑡

(71)
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𝑒

𝑐 𝑑𝑡 = 𝑐

𝑒

−1
𝑒
𝐾

𝑑𝑡 = 𝑐

=

−𝑐
𝐾

(72)

With these in hand, the governing equation for the steady problem can be rendered
simply as:
𝐷

𝜕 𝑐
𝐾𝐾
+ 𝐾 −
𝜕𝑥
𝐾

𝑐

(73)

This effectually represents an undamped second-order system with the roots, 𝑚 , ,
where:
−𝐷 𝐾 −
𝑚

,

=±

𝐾𝐾
𝐾

(74)

𝐷

Recall that all of the pharmacokinetic coefficients, 𝐷, 𝐾 , 𝐾 , 𝐾 , 𝐾 , 𝑉 and 𝑉 , are all
positive, therefore, the roots 𝑚

,

are always real and distinct, yielding the steady solution

to be:
𝑐 (𝑥) = 𝜂 𝑒

−

1
𝑒

(75)

Where:
𝑐

𝜂=
𝑒

−

1

(76)

𝑒

Transient Solution
Given the linearity of the problem, with only a single non-homogeneity in the governing
equation, a separation of variable approach is implemented to solve the transient problem.
Here, it is assumed that the transient solution, 𝑐 (𝑥, 𝑡), is the product of two independent
Eigen functions, 𝜒(𝑥) and 𝜏(𝑡) for the spatial and temporal spaces respectively, where:
𝑐 (𝑥, 𝑡) = 𝜒(𝑥)𝜏(𝑡)
Making this substitution in the governing equation for the transient solution yields:

(77)
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𝜒

𝜕𝜏
𝜕 𝜒
= 𝐷𝜏
+ 𝐾 𝜒𝜏 + 𝐾 𝐾 𝑒
𝜕𝑡
𝜕𝑥

𝜒

𝑒

𝜏 𝑑𝑡

(78)

A more compact representation is given by implementing a slight change of notation as:
𝜒𝜏̇ = 𝐷𝜒 𝜏 + 𝐾 𝜒𝜏 + 𝐾 𝐾 𝑒

𝜒

𝑒

𝜏 𝑑𝑡

(79)

Given the separation of variables approach, we seek to cast the transient solution in a
form convenient for separating the Eigen functions. To do so requires the elimination of
the integral term, accomplished by deriving equation (79) with respect to time. This
process is not entirely straightforward, contributes little to the final understanding of the
solution, and is rather cumbersome, and therefore is not shown here. However, it allows
the Eigenfunctions to be separated in a manner that yields the following equation:
𝜏̈ − [𝐾 + 𝐾 ]𝜏 − [𝐾 𝐾 − 𝐾 𝐾 ]𝜏 𝜒
=
𝐷𝜏̇ − 𝐾 𝐷𝑡
𝜒

(80)

Given the independence of the solution domains for the two Eigen functions, this
equation can only hold true if the left- and right-hand sides of the equation are equal to
some constant, referred to as the separation constant, nominally assigned a value of ±𝜆 .
This separation constant is chosen to be a negative, −𝜆 , in order to arrive at an
oscillative Eigenfunction solution in the spatial domain, given the homogenous boundary
conditions.
𝜏̈ − [𝐾 + 𝐾 ]𝜏̇ − [𝐾 𝐾 − 𝐾 𝐾 ]𝜏 𝜒
=
= −𝜆
𝐷𝜏̇ − 𝐾 𝐷𝑡
𝜒

(81)

By allowing the separation constant to be negative, the spatial component of the solution
can then be cast in the form:
𝜒 +𝜆 𝜒=0
Thus, the spatial Eigenfunction, 𝜒(𝑥), becomes:

(82)
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(83)

𝜒(𝑥) = sin(𝜆 𝑥)

With the separation constant yielding the Eigenvalues of the function, 𝜆 , which are
defined as:
𝜆 =

𝑛𝜋
, 𝑛 ∈ [0, ∞)
𝐿

(84)

Briefly, the Eigenvalues are valid on the domain 𝑛 ∈ [0, ∞), but given the zero value of
the Eigenvalue and Eigenfunction at 𝑛 = 0, the system is henceforward represented on
the domain of 𝑛 ∈ [1, ∞), as will become apparent shortly.
Notice that the representation of the temporal Eigen function also takes the form of a
second-order system, but one that is damped:
𝜏̈ − 𝐾 + 𝐾 − 𝐷𝜆

𝜏̇ − [𝐾 𝐾 − 𝐾 𝐾 + 𝐾 𝐷𝜆 ]𝜏 = 0

(85)

The system defining the temporal Eigenfunction has roots which are always real, distinct,
and negative, defined such that:
𝐾 + 𝐾 − 𝐷𝜆
𝑠

,

±

=

𝐾 − 𝐾 − 𝐷𝜆

+ 4𝐾 𝐾

(86)

2

This produces a solution that takes the form of an asymptotic exponential Eigen function,
where:
𝜏(𝑡) = 𝜎 𝑒

+𝜎 𝑒

(87)

The coefficients, 𝜎 and 𝜎 , are as of yet undefined, but must be found to arrive at a
particular solution and is accomplished by imposing the initial conditions of the problem.
However, one must first recognize that, by superposition, the transient solution is in fact
the combination of the Eigenfunctions at all wavelengths, 𝜆 , to form the general
solution, where:
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𝑐 (𝑥, 𝑡) = 𝜒(𝑥)𝜏(𝑡) =

[𝜎 𝑒

+𝜎 𝑒

(88)

] sin(𝜆 𝑥)

The first initial condition is readily apparent: the unbound compound concentration in the
dermis is zero at our initial time, 𝑡 = 0. Thus, the transient solution at the initial time
must be equal to the negative of the steady solution. Applying this information, we have:
−𝑐 (𝑥) =

𝜎

,

+𝜎

,

(89)

sin(𝜆 𝑥)

Here, the principle of orthogonality can be applied to move in the direction of a solution
for the unknown constants, 𝜎 and 𝜎 , where:
−𝑐 (𝑥) sin(𝜆 𝑥) 𝑑𝑥 =

𝜎

,

+𝜎

,

sin (𝜆 𝑥) 𝑑𝑥

(90)

The above integration utilizes the orthogonal behavior of the Eigenfunction, here,
sin(𝜆 𝑥), to simplify the above relationship. Again, this integration is quite cumbersome
and is not repeated in this work. However, the above integration yields the following
relationship:
𝜎

,

+𝜎

,

= (−1)

2𝜂𝑛𝜋[𝑒
−𝑒
𝑚 𝐿 +𝑛 𝜋

]

(91)

The second initial condition is perhaps a little less obvious but has been mentioned in
passing already. We will start with equation (62), observing the form of the equation at
the initial time, 𝑡 = 0.
𝜕𝑐(𝑥, 0)
𝜕 𝑐(𝑥, 0)
=𝐷
+ 𝐾 𝑐(𝑥, 0) + 𝐾 𝐾 𝑒
𝜕𝑡
𝜕𝑥

𝑒

𝑐 𝑑𝑡

(92)

Note that the integral term is representative of the accumulation of the compound within
the unbound compartment of the dermis up to time 𝑡 = 0. The assumption made for the
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initial state of the domain is that the dermis is initially clear of the compound being
transported. This means that the accumulation of the compound in the dermis is zero; this
assumption coincides with the assumption that the dermal concentration of the compound
in the bound compartment is also zero initially. This information, coupled with the zero
unbound concentration for the entirety of the domain, yields our second initial condition.
Therefore:
𝜕𝑐(𝑥, 0)
= 𝜒(𝑥)𝜏̇ (𝑡) =
𝜕𝑡

𝑠

,

𝜎

+𝑠

,

,

𝜎

,

sin(𝜆 𝑥) = 0

(93)

From the above, a relation between the coefficients 𝜎 and 𝜎 is readily apparent, such
that:
𝜎

,

=−

𝑠

,

𝜎

𝑠

,

,

(94)

This then yields a direct expression for the coefficients:
𝜎

𝜎

,

= (−1)

,

= (−1)

2𝑛𝜋𝑐
𝑚 𝐿 +𝑛 𝜋

𝑠,
𝑠 , −𝑠

2𝑛𝜋𝑐
𝑚 𝐿 +𝑛 𝜋

𝑠,
𝑠 , −𝑠

(95)
,

(96)
,

Thus, the analytical solution is complete and given below, with all the terms that define
this equation expressed above in terms of knowns.
𝑐(𝑥, 𝑡) = 𝜂 𝑒

−

1
𝑒

+

𝜎, 𝑒

,

+𝜎 , 𝑒

,

sin(𝜆 𝑥)

(97)

Analytical Solution Representation
Unfortunately, rendering the exact solution for numerical study is an impossibility, given
the infinite sum required by the Eigen function representation. However, a practical
approximation of the analytical solution can be found by using a truncated, finite
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representation of the infinite sum. Rather than attempting an infinite sum, a finite sum
can be accurate enough for application; that is to say, instead of summing over the
Eigenvalue domain of 𝑛 ∈ [1, ∞), one can instead sum over the domain of 𝑛 ∈ [1, 𝑁],
given a large enough value of 𝑁.
To qualify what exactly is a “large enough” value of 𝑁, one measures the percent change
in the pseudo-analytical solution as the number of summed Eigen functions, 𝑁, increases.
As 𝑁 tends towards infinity, this approximation converges on the true analytical solution.
Thus, the percent change in the solution is representative of a percent increase in
accuracy of the representation. Integrating this change in solution accuracy with a change
in 𝑁 represents the convergence of the representation.

Figure 8: Convergence order of the analytical solution with increasing Eigenfunction
representation with (a) in the linear scale [𝑁] and (b) in the log scale [log 𝑁] for clarity

From this information, one notes that even a truncation with as few as 200 superimposed
Eigen functions will be sufficient in representing the analytical solution; with a
summation spanning 200 Eigen functions, 𝑁 = 200, the solution has converged to about
96.0% of the analytical solution as calculated with 10,000 Eigen functions, 𝑁 = 10,000.
At 500 Eigen functions, 𝑁 = 500, the solution captures approximately 98.5% of the
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solution at 𝑁 = 10,000. With a negligible increase in computation time to arrive at a
solution with 500 Eigen functions, as compared to 200 Eigen functions, the numerical
solution is compared to the analytical solution with 𝑛 ∈ [1, 500].
It is the authors hope that this process demonstrates that an analytical solution is neither
trivial, nor very practical, even for the 1D case. Furthermore, an analytical solution may
very well be impossible for more complex cases of this same type of problem, i.e., with
non-trivial initial conditions, time-varying boundary conditions, irregular geometries, and
higher-dimensional domains, etc. Thus, the need for a numerical technique that provides
the possibility of simulation or approximate solution in an efficient manner.
3.3.2. Solution Comparison
To compare the analytical solution to a numerical solution, the problems need to be setup
for equivalence between the domains, boundary conditions and initial conditions of the
solutions. Many of these conditions can be best explained through a visualization
followed by a table of conditions given in Table 1.
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Figure 9: 2D Numerical domain, with boundaries setup to replicate one-dimension analytical
solution. Domain not to scale.
Table 1: Boundary conditions for 2D numerical domain

Index

Boundary

Boundary Description

Boundary Type

Boundary Value

1

Top

Microneedle Tip

First-kind

43 mg/mL

2

Bottom

Dermal Bed

First-kind

0 mg/mL

3

Left

Symmetric

Second-kind

0 mg/cm4

4

Right

Symmetric

Second-kind

0 mg/cm4

The length of the domain in the depth-wise or x-coordinate was 𝐿 = 0.2 [𝑐𝑚], the
average thickness of viable dermis [8]. The width of the domain in in the y-coordinate is
effectively arbitrary, given the symmetric boundary conditions at the lateral extents,
however, 𝑊 = 0.2 [𝑐𝑚] was implemented, to ensure there were no edge effects at the
center of the domain.
As the analytical solution is 1D solution, the 2D numerical domain can behave as a 1D
solver by implementing symmetric boundary conditions in the coordinate perpendicular
to the depth-wise coordinate. The initial conditions are straightforward and similar for
both domains where:
𝑐(𝒙, 0) = 0

(98)

In evaluating the numerical solution, six sets of pharmacokinetic parameters were used;
three sets of parameters are given by Anderson et al., Eichelbaum et al. and Koike et al.,
and following Al-Qallaf each set is used once with and once without metabolism [15],
[84]–[86]. In all cases, the diffusion coefficient and metabolic rate constant are the same,
where:
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𝐷 = 7.8 ∙ 10

(99)

[𝑐𝑚 /𝑠]

𝐾 = 5.61 ∙ 10

(100)

[1/𝑠]

The remaining sets of parameters are tabulated in Table 2 for clarity [15], [84]–[86].
Table 2: Sets of pharmacokinetic parameters in analytical validation

𝐾 [1/𝑠]

𝐾 [1/𝑠]

𝑉 [𝑚𝐿]

𝑉 [𝑚𝐿]

(x10-4)

(x10-4)

(x10-4)

(x104)

(x104)

Anderson, et al

1.58

2.19

1.11

5.18

2.63

Eichelbaum, et al

0.79

2.12

2.78

13.14

27.39

Koike, et al

1.5

6.22

3.94

8.34

6.47

𝐾

[1/𝑠]

The Normalized Root Mean Square Error (NRMSE) was applied to the provide some
quantifiable measure of the difference between the numerical solution, 𝑐 (𝒙, 𝑡), and the
analytical solution, 𝑐 (𝒙, 𝑡). The NRMSE was the metric of choice, as 1) It is an
extension of the Frobenius norm, and therefore gives an indication of the distance
between two matrices of solutions, 2) It is normalized by the number of data points in the
solution, and therefore should not by swayed by the resolution of the solution, and 3) It is
normalized by the span of the analytical solution, meaning that the choice of boundary
conditions should not affect the measure of error from any particular case to another [87].
The equation of the NRMSE, as implemented here is given as:
1
∑ [𝑐 (𝒙𝒊 ) − 𝑐 (𝒙𝒊 )]
𝑁
𝑁𝑅𝑀𝑆𝐸 =
|𝑚𝑎𝑥[𝑐 (𝒙𝒊 )] − 𝑚𝑖𝑛[𝑐 (𝒙𝒊 )]|
Where:
𝑁 = Number of data points in the matrix of solution values

(101)
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3.3.3. On Convergence
Recall from Madych that the approximation error for the global collocation method is on
the order of 𝑂 𝑒 𝜆

/

[71]. Of course, for localized methods, there is no theoretical

bound that has been developed for the error, but an experimentally derived convergence
rate is given by Ding et al., estimating the error as being on the order of 𝑂((ℎ/𝑐) ),
where ℎ refers to the spacing of data centers in the solution with 𝑐 referring to the shape
factor of the RBFs used in the collocation. Already discussed is the automated
optimization of the shape factor on each topology, and so the convergence behavior here
is sought with respect to the nodal spacing within the domain; that is, how does ℎ impact
the approximation error for the LCMM. To understand this behavior, the numerical
solution is sought over a range of nodal densities and the NRMSE is calculated for each
numerical solution against its respective analytical solution. This is conducted over 40
different values of nodal densities for all six sets of pharmacokinetic parameters, as
established in the above section, Section 3.3.2, in Table 2. The range of nodal densities is
given by the number of nodes along the depth-wise axis. The number of nodes used along
the x-coordinate to refine the nodal density, 𝑛 , is given as a function of case number, 𝑛 ,
where:
𝑛 = 3 + 2𝑛

(102)

Where 𝑛 ∈ [1, 40]. Given that the length of the domain in the x-coordinate is fixed to
𝐿 = 0.2 𝑐𝑚, the nodal spacing, ℎ, can be calculated as:
ℎ=

𝐿
𝑛

To illustrate this relationship, a few sample values are given below in Table 3.

(103)
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Table 3: Case number versus number of nodes and spacing in depth-wise coordinate

𝑛

𝑛

ℎ [𝑐𝑚]

1

5

0.04

⁝

⁝

⁝

21

45

0.008

22

47

0.00444

23

49

0.004255

⁝

⁝

⁝

40

83

0.00241

3.4. Sensitivity Study
As a part of the development of the LCMM to the problem of pharmacokinetics, a
sensitivity study is conducted to evaluate the effects of parameter variation on the
solution space, but more importantly, to ensure that the numerical framework is
insensitive to input parameters, or rather, that varying inputs do not cause instabilities in
the solution method.
Accordingly, a baseline simulation is established where some initial concentration of
Verapamil is injected into the skin, here, 30 mg/mL, and allowed to freely diffuse
through the dermis. The initial condition and free diffusion of Verapamil are
demonstrated below in Figure 10 for illustrative purposes.
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Figure 10: Free diffusion of Verapamil for sensitivity study

However, the boundary conditions used here differ slightly from the analytical
comparison. In this case, the top-most surface, where the viable dermis meets the stratum
corneum is a second-kind boundary condition, with flux of 0 mg/cm 4. This is done to
prevent the back propagation of the Verapamil through the stratum corneum and out of
the skin, reflecting the low-diffusivity of the stratum corneum and its barrier-like
properties [28], [88]. The remaining details for the setup of the domain will be given in
the details of the inverse problem, as the sensitivity study is a precursor to the inverse
problem, and therefore shares the same domain.
The baseline simulation uses the pharmacokinetic parameters given by Koike, used in the
above numerical convergence study, and are tabulated below for convenience in Table 4.
The sensitivity study functions by varying each pharmacokinetic parameter by one order
of magnitude, first increasing the order of the parameter and then decreasing the order of
the parameter and noting differences in transport behavior. Instead of varying the
volumes of the bound and unbound compartments independently, the ratio of the
volumes, 𝜈 , was varied, as the two volumes are always used in conjunction together,
where:
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𝜈 =

𝑉
𝑉

(104)

Iterating the order of magnitude of each pharmacokinetic parameter yields the following
cases to be run:
Table 4: Sets of pharmacokinetic parameters for sensitivity study

𝐷 [𝑐𝑚 /𝑠]

𝐾 [1/𝑠]

𝐾 [1/𝑠]

𝐾 [1/𝑠]

(x10-8)

(x10-4)

(x10-4)

(x10-4)

(x10-4)

Baseline

7.8

5.61

1.5

6.22

3.94

0.1

1

0.78

5.61

1.5

6.22

3.94

0.1

2

78.0

5.61

1.5

6.22

3.94

0.1

3

7.8

0.561

1.5

6.22

3.94

0.1

4

7.8

56.1

1.5

6.22

3.94

0.1

5

7.8

5.61

0.15

6.22

3.94

0.1

6

7.8

5.61

15.0

6.22

3.94

0.1

7

7.8

5.61

1.5

0.622

3.94

0.1

8

7.8

5.61

1.5

62.2

3.94

0.1

9

7.8

5.61

1.5

6.22

0.394

0.1

10

7.8

5.61

1.5

6.22

39.4

0.1

11

7.8

5.61

1.5

6.22

3.94

0.01

12

7.8

5.61

1.5

6.22

3.94

1.0

𝐾

[1/𝑠]

𝜈 [−]

3.5. Inverse Problem – Parameter Identification
There are significant difficulties in measuring compound concentration in vivo, making
the practice almost non-existent. Traditionally, diffusion coefficients are estimated from
in vitro experiments utilizing steady-state skin concentrations, leading to less reliable
quantifications of the actual unbound diffusion coefficient [88], [89]. This is contrasted to
other pharmacokinetic parameters which can be extracted from readily available systemic
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observations [17], [84]–[86]. However, work published by Kretsos poses the concept of
the “free diffusivity coefficient,” based on the molecular weight (MW) of a compound
[20]. This empirically derived free diffusivity coefficient may provide information that
can be combined with this numerical tool to better estimate in vivo diffusivity
coefficients.
3.5.1. Free Diffusion Analogue
In the work by Kretsos et al., partition coefficients and diffusivities were studied using
both experimental techniques and through a literature review [20]. In the experimental
methods, Kretsos quantified the partition and diffusion coefficients using a steady-state
diffusion approach. The paper also reviewed 11 publications, based primarily on in vitro
steady-state flux experiments which estimate partition and diffusion coefficients for 30
compounds, as well as 8 publications which conducted in vivo studies of skin
concentrations of 9 topically transported compounds. In addition to the partition and
diffusion coefficients, some binding factor, 𝑓 , was calculated for each of the compounds
from other parameters either readily available or derived from data in the literature
review. In this work, Kretsos et al. correlated the free diffusivity, 𝐷

, and effective

diffusivity, 𝐷 , by this binding factor, 𝑓 , where:
𝐷

=

𝐷
𝑓

(105)

These free and effective diffusion coefficients both have corresponding concentrations,
𝐶

and 𝐶 , respectively, that diffuse in accordance with these diffusion coefficients.

The distinction of the free variables, 𝐷

and 𝐶

, from the effective variables, 𝐷

and 𝐶 , is that the effective terms describe behavior that is subject to partitioning and
binding effects. These freely diffusing variables results in a slightly modified model of
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the transport equations. Again, these free variables are not subject to effects such as
binding and partitioning [20]. Therefore, the free transport model reduces to a simple
diffusion equation, where:
𝜕𝑐
=𝐷
𝜕𝑡

𝛻 𝑐

(106)

The effective diffusion coefficients and corresponding free diffusion coefficients derived
from the literature survey are tabulated and graphed below in Appendix A, Table 14 and
Figure 11 respectively. It is worth noting that in Tojo’s experiments, the preparation of
the mouse dermis was inconsistent with other studies and yielded drastic differences in
the predicted diffusion coefficient. Therefore, this data is excluded from the Kretsos’s
formulation.

Figure 11: Diffusion coefficients versus molecular weight: (a) Effective diffusion coefficient
versus and (b) Free diffusion coefficients versus molecular weight. In both cases, there is strong
correlation to the Wilke-Chang Relationship (dotted line) [20].
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The following equation, given by Kretsos et al. represents “the line of perfect fit” for the
data given by the experiments and the literature review [20].
log 𝐷

= −4.15 − 0.655 log 𝑀𝑊

(107)

Where:
𝑀𝑊 = Molecular weight of the compound in Daltons [𝐷𝑎]
The concentration in equation (106) serves as an analogue to the concentration given by
equation (10) in the full model as defined by the set of PDEs.
3.5.2. Objective Function Minimization – Golden Section Search
If the concentrations are analogous, then the free diffusion equation, equation (106), can
be used to inversely identify the unbound diffusion coefficient in equation (10). This is
done by minimizing the distance between the free concentration field solution, 𝑐

, and

the unbound concentration field solution, 𝑐, as quantified by the L2-norm between the
solutions [90]:

𝐿 =

1
𝑁

𝑐(𝒙𝒊 ) − 𝑐

(𝒙𝒊 )

(108)

Essentially, this is a one-dimensional search for the diffusion coefficient to implement in
equation (10), and the objective function is the L2-norm utilizing the Frobenius norm to
measure the distance between the field solutions [87]. Despite the simplicity of a onedimensional search, there is no analytical relationship between the objective function and
the design variable, 𝐷, that is readily available for analytical or traditional gradient-based
approaches. Therefore, the golden section search (GSS) algorithm is implemented for this
minimization, given its speed and simplicity in unidimensional optimization [91].
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GSS is a technique that is similar to the well-known bisection method for root-finding, in
that this method implements a dividing region concept [92]. However, bisection
necessitates a sign-change in the objective function, an impossibility given the L2-norm
definition provided. GSS evaluates the objective function at two locations and attempts to
determine a bound on the domain within which the minimum exists, using this bound to
iterate again and again, making the bounds smaller and smaller until either (a) a “good
enough” value is obtained from the objective function for the design variable in question,
(b) the span of the bounds on the design variable is “small enough,” or (c) a maximum
number of iterations has been reached.
For illustration, consider the design variable, 𝐷, bounded by 𝐷 ∈ 𝐷

,𝐷

, with

the fitness function to be minimized, 𝑓(𝐷), representing the L2-norm for the space and
given below in Figure 12. This function is spanned by the range 𝑑 = 𝐷
the below example, for the first iteration, 𝑑 = (10 − 0) = 10.

Figure 12: Example Unimodal Function

−𝐷

, in
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From here, two sample points, 𝐷 and 𝐷 , are calculated using the golden ratio, 𝜑, such
that:
𝜑=

√5 − 1
2

𝛿 = 𝜑𝑑 = 𝜑 𝐷

(109)
(110)

−𝐷

𝐷 =𝐷

+𝛿

(111)

𝐷 =𝐷

−𝛿

(112)

The fitness function is evaluated at the two samples points, returning 𝑓(𝐷 ) and 𝑓(𝐷 ),
which are then compared.

Figure 13: Example Unimodal Function, GSS Iteration, 𝑖 = 1

If 𝑓(𝐷 ) < 𝑓(𝐷 ), as exemplified in Figure 13, then it is assumed that the minimum
exists within the bounds 𝐷 , 𝐷

. If the converse were to be true, that is, if 𝑓(𝐷 ) <

𝑓(𝐷 ),then the assumption is made that the minimum exists within the bounds
[𝐷

, 𝐷 ]. These bounds become the new upper and lower bounds, 𝐷

,𝐷

,

for the next iteration. Then, 𝛿 is recalculated using these new bounds, followed by
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calculating new sample points, 𝐷 and 𝐷 , with the corresponding fitness evaluation at
these new samples, 𝑓(𝐷 ) and 𝑓(𝐷 ). It is worth noting that because the golden ratio is
used to find the new sample points, there will always be one new sample point coinciding
with a sample point from a previous iteration. This means that for each iteration, only one
new calculation or solution is required, saving a significant amount of computation when
each new calculation requires a significant amount of computation, as is the case for an
entire field solution. To demonstrate this behavior, the next iteration is provided below in
Figure 14. Comparing sample point 𝐷 in Figure 14 to sample point 𝐷 in Figure 13
makes the shared sample point location quite apparent.

Figure 14: Example Unimodal Function, GSS Iteration, 𝑖 = 2

Again, this iteration is repeated until one of the above conditions is met; (a) a specific L2norm or fitness is met, (b) the span, 𝑑, becomes sufficiently small, indicating some
minima has been found, or (c) the maximum number of iterations has been reached.
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The search is quite efficient, converging exponentially with the number of iterations.
Given an initial span for the design variable, 𝑑 = 𝐷

−𝐷

, the GSS reduces this

span by the golden ratio each iteration, that is, at any iteration, 𝑖, the span will be:
𝑑 =𝜑𝑑

(113)

This means that in 10 iterations, or 11 evaluations of the solution, the GSS will have
ruled out about 99.2% of the initial bounds. That is,
𝑑

= 0.008𝑑

(114)

3.5.3. Elimination Extension
However, the minimization demonstrates a significant disagreement between the two
models, due to the elimination effects. Therefore, it is imperative that metabolism and
clearance are incorporated into the freely diffusing model given in equation (106), by
including first-order elimination in the reduced model. Accordingly, consider the
following extension to the free-diffusion model, which implements first-order elimination
effects.
𝜕𝑐
=𝐷
𝜕𝑡

𝛻 𝑐 − 𝐾𝑐

(115)

This elimination coefficient, 𝐾, must, in some fashion, account for (a) the metabolic
effects in the unbound compartment, as well as (b) the elimination effects in the bound
compartment. To do so in the exact sense, the following relationship must be met:
𝐾𝑐 = 𝐾 𝑐 + 𝐾 𝑐

(116)

Though an exact, time-accurate relationship between the bound and unbound coefficients,
𝑐 and 𝑐 ,necessitates a more elaborate analytical solution, an approximation can be made
by leveraging the partition coefficients, which describe the steady-state separation of the
compound into the two compartments of the binary mixture. Consider the concentration
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storage equation for the bound compartment given in equation (11). The concentration
adsorbed into the bound from the unbound compartment, 𝑐

→

, can be given by the

central term:
𝑐

→

∝

1
𝐾 𝑐−𝐾 𝑐
𝜈

(117)

With some simple algebraic manipulation, one arrives at the steady state partitioning
approximate for the compound in the dermis that is bound relative to the unbound
concentration as:
𝑐 ≈

𝐾
𝑐
𝜈 (1 + 𝐾 )

(118)

Substituting this relationship into equation (116) yields:
𝐾𝑐 = 𝐾 𝑐 + 𝐾

𝐾
𝐾
𝑐 = 𝐾 +𝐾
𝑐
𝜈 (1 + 𝐾 )
𝜈 (1 + 𝐾 )

(119)

With this small extension of first-order elimination to the free-diffusion equation, there is
a significant improvement in attainable values for the L2-norm in the minimization effort,
showing much greater agreement between the extended free-diffusion model and the full,
two-compartment model. Therefore, it is the extended free-diffusion model used in the
inverse parameter problem to identify the diffusion coefficient for a compound.
3.5.4. Domain Setup
For the inverse problem, the domain is setup to reflect a simple injection pattern, as
demonstrated in Figure 10, and reprinted below for convenience to the reader.
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Figure 15: Inverse problem domain

The domain has a depth of 0.12 cm, the average thickness of skin in the face, and a width
of 1.0 cm, which is somewhat arbitrary, but setup to allow the initial injection to diffuse
uninhibited through the domain [93]. The domain begins with an initial concentration of
30 mg/mL, injected by a 33 gauge into the dermal layers, as shown above in Figure 15.
The compound is allowed to diffuse freely through the dermis over an 8-hour simulation.
At the bottom of the domain, the same dermal bed sink boundary condition is applied
such that:
𝑐|

= 0 [𝑚𝑔/𝑚𝐿]

(120)

At the top of the domain, an insulative boundary condition is applied, representing the
relative impermeability of the stratum corneum, preventing the back-diffusion of the
compound, such that [15], [28]:
𝜕𝑐
𝜕𝑛

= 0 [𝑚𝑔/𝑚𝐿 ∙ 𝑐𝑚]

(121)

.

At the left and right boundaries, symmetry conditions are applied, replicating the
potential multiple injection sites under consideration in the application of interest. The
symmetry conditions are specified such that:
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𝜕𝑐
𝜕𝑛

(122)

= 0 [𝑚𝑔/𝑚𝐿 ∙ 𝑐𝑚]
,

This inverse methodology is generic and can be applied to any compound. Given, the
prevalence of literature defining the pharmacokinetic parameters, Verapamil is used for
demonstration of the meshless solution and inverse methodology. The pharmacokinetic
parameters for Verapamil are as follows, and are given by Anderson and Al-Qallaf [15],
[84]:
Table 5: Pharmacokinetic parameters employed in PID problem set

Anderson, et al

𝐾 [1/𝑠]

𝐾 [1/𝑠]

𝐾 [1/𝑠]

-4

-4

-4

𝐾

[1/𝑠]
-4

(x10 )

(x10 )

(x10 )

(x10 )

5.61

1.58

2.19

1.11

𝜈 [−]
0.51

The molecular weight of Verapamil is given in Daltons as [94]:
𝑀𝑊 = 454.6 [𝐷𝑎]

(123)

Which, according to equation (107), yields a free-diffusion coefficient of:
𝐷

= 1.067 ∙ 10

[𝑐𝑚 /𝑠]

(124)

3.6. Volume-of-Fluid Method – Progressive Piping
The Volume-of-Fluid (VOF) Method poses a potential solution to inverse geometry
problems evaluated using the LCMM. It has been mentioned that calculations made with
respect to the topology, such as the derivative precomputation, typically can be used from
one time-step to another, or even between solutions. This is only true in cases where the
topology does not change from one calculation step to another; this means that if the
location of a data center changes, or the topologies change which nodes are included or
excluded, then the calculations are no longer valid. This typically is not an issue in most
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calculations but is just about guaranteed in problems of inverse geometry. While the
LCMM will not suffer the same overhead of remeshing each new domain, and therefore
is already significantly more efficient than traditional meshed methods, being able to save
on these calculations can provide a significant improvement in dedicated inverse
geometry studies.
The VOF Method allows the tracking of some VOF parameter, 𝑠, which defines the
interface or surface between two regions in the domain. This VOF parameter can be used
to weight the value of physical properties in the domain between these two regions [82].
Although not directly applied to the pharmacokinetic problem, an LCMM VOF approach
is developed in application to progressive piping. The fundamentals of its development
could, in theory, be extended to the pharmacokinetic problem as a method of handling the
moving interface between the microneedles and the dermis, hence, mitigating the
changing domain by instead changing the interfacing surface within the domain.
The meshless VOF method finds application to the progressive piping problem;
progressive piping is defined as the formation and gradual expansion of internal voids
within water-retaining structures, such as dams and levees, usually leading to the collapse
of the structure. A schematic of the problem is given below in Figure 16.

Figure 16: Schematic of the groundwater flow, depicting progressive piping
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Progressive piping is founded in the equations that govern flow through poroelastic
media, beginning with the Navier equation coupled with the Richards equations as:
𝐺∇ 𝑢 +

𝜑𝛽

𝐺
∇(∇ ∙ 𝑢⃗) = ∇𝑝
1 − 2𝜈

𝜕𝑝
𝜅
=∇∙
∇𝑝 + 𝜌 𝑔⃗
𝜕𝑡
𝜇

−

𝜕
(∇ ∙ 𝑢⃗)
𝜕𝑡

(125)
(126)

Where:
𝑝 = Pore pressure [𝑃𝑎]
𝜑 = Porosity of the medium [−]
𝜅 = Permeability of the medium [−]
𝛽 = Compressibility of the fluid [𝑚 /𝑁]
𝜌 = Density of the fluid [𝑘𝑔/𝑚 ]
𝜇 = Viscosity of the fluid [𝑃𝑎 ∙ 𝑠]
An important parameter in fluid flow through porous media is they hydraulic
conductivity, which is defined as:
𝐾 =

𝜅𝜌 |𝑔⃗|
𝜇

(127)

The Darcy velocity of the flow through the porous medium is defined as:
𝑉⃗ = −

𝜅
∇𝑝 + 𝜌 𝑔⃗
𝜇

(128)

Therefore, the actual front velocity of the flow is given by:
𝑉⃗ =

𝜕𝑢⃗
𝜅
−
𝜕𝑡 𝜑𝜇

∇𝑝 + 𝜌 𝑔⃗

(129)
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The front velocity of the flow, 𝑉⃗ , is used to track the location of the saturation lime
within the porous medium. The location of the saturation line, 𝑠, at any time-level can be
traced by a transport equation as:
𝜕𝑠
+ 𝑉⃗ ∙ ∇ 𝑠 = 0
𝜕𝑡

(130)

This VOF parameter, 𝑠, can be used to weight the value of the physical properties
between the saturated and unsaturated values as:
𝐺 = (1 − 𝑠)𝐺 + 𝑠𝐺

(131)

Where:
𝐺 = Shear modulus of the unsaturated medium
𝐺 = Shear modulus of the saturated medium
The microneedle optimization is one such problem that can benefit from this formulation,
as the interface defining the microneedle-dermal boundary can be defined using a VOF
approach, potentially weighting the diffusion coefficient within the domain. This VOF
surface can be varied between solutions, thereby changing the microneedle geometry
without changing the domain.
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4. Results
There are several sets of results to be presented, as several problems have been evaluated
for the development of this numerical framework. It is the author’s hope that the order of
the results presented is in such a way so as to contribute to the understanding of the
overall progression of the numerical framework.
First, results will be given for the analytical validation of the LCMM, as the validation
provides meaningful context by which simulation results can be evaluated. These will be
followed by the results from the convergence study, demonstrating the robustness of the
solution. Finally, results from the inverse problem will be provided to observe how the
LCMM functions in problems of higher complexity. As a sort of addendum, some
qualitative results from the LCMM-VOF method will be provided, demonstrating a future
capability that is currently in development.
4.1. Analytical Validation
4.1.1. Experimental Setup
The domain for the analytical solution and numerical solutions are setup for equivalence
between the two solutions in quantifying the depth-wise concentration profile of the
transported compound, here, Verapamil.
Since this essentially a study of a one-dimensional problem, we begin with the setup of
the analytical solution, as it is a true one-dimensional problem, and the setup is fairly
simple. In the analytical solution, boundary and initial conditions as specified in Table 6
are applied.
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Table 6: Initial and boundary conditions for analytical solution

Location

Condition

Description

Boundary Type

Value

𝑐(𝑥, 0)

Initial Condition

Dermal Bed

-

0 mg/mL

𝑐(0, 𝑡)

Boundary Condition

Dermal Bed

First-kind

0 mg/mL

𝑐(𝐿, 𝑡)

Boundary Condition

Microneedle Tip

First-kind

𝑐

mg/mL

Additionally, the analytical solution requires the sum of an infinite number of Eigen
functions, which can be approximated by a limited number of Eigen functions,
particularly 500 Eigen functions. At 500 Eigen functions, 𝑁 = 500, the solution captures
approximately 98.5% of the solution at 𝑁 = 10,000, with a negligible increase in
computation relative to 200 Eigen functions.

Figure 17: Convergence order of the analytical solution with increasing Eigen function
representation with (a) in the linear scale [𝑁] and (b) in the log scale [log 𝑁] for clarity

The numerical solution has a very similar domain setup but requires an extra step for the
two-dimensional domain to behave as a one-dimensional domain, and that is to apply
symmetric conditions at the width boundaries. These initial and boundary conditions are
specified below in Table 7.
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Table 7: Initial and boundary conditions for numerical solution

Location

Condition

Description

Boundary Type

Value

𝑐(𝑥, 𝑦, 0)

Initial Condition

Dermal Bed

-

0 mg/mL

𝑐(𝑥, 0, 𝑡)

Boundary Condition

Dermal Bed

First-kind

0 mg/mL

𝑐(𝑥, 𝐿, 𝑡)

Boundary Condition

Microneedle Tip

First-kind

𝑐(0, 𝑦, 𝑡)

Boundary Condition

Symmetry

Second-kind

0 mg/cm4

𝑐(𝑋, 𝑦, 0) Boundary Condition

Symmetry

Second-kind

0 mg/cm4

𝑐

mg/mL

The domains of the two problems are effectively demonstrated in Figure 9 which is
recreated below for convenience.

Figure 18: Domain setup for analytical convergence study
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There are several sets of parameters for Verapamil given from three separate studies, and
each set of pharmacokinetic parameters is used in the convergence study. Each set of
parameters was used to evaluate the solution convergence first, with metabolism, 𝐾 =
[1/𝑠], and then without metabolism, 𝐾 = 0 [1/𝑠], to replicate the study by

5.61 ∙ 10

Al-Qallaf et al., resulting in six cases to be evaluated. The sets of parameters are given
below in Table 8 and Table 9, noting that in the diffusion coefficient is the same [15],
[84]–[86].:
𝐷 = 7.8 ∙ 10

(132)

[𝑐𝑚 /𝑠]

Table 8: Sets of pharmacokinetic parameters for analytical convergence study

𝐾 [1/𝑠]

𝐾 [1/𝑠]

𝑉 [𝑚𝐿]

𝑉 [𝑚𝐿]

(x10-4)

(x10-4)

(x10-4)

(x104)

(x104)

Anderson, et al

1.58

2.19

1.11

5.18

2.63

Eichelbaum, et al

0.79

2.12

2.78

13.14

27.39

Koike, et al

1.5

6.22

3.94

8.34

6.47

𝐾

[1/𝑠]

Table 9: Extended sets of pharmacokinetic parameters for analytical convergence study

𝐾 [1/𝑠]

𝐾 [1/𝑠]

𝐾 [1/𝑠]

𝑉 [𝑚𝐿]

𝑉 [𝑚𝐿]

(x10-4)

(x10-4)

(x10-4)

(x10-4)

(x104)

(x104)

1

5.61

1.58

2.19

1.11

5.18

2.63

2

0.0

1.58

2.19

1.11

5.18

2.63

3

5.61

0.79

2.12

2.78

13.14

27.39

4

0.0

0.79

2.12

2.78

13.14

27.39

5

5.61

1.5

6.22

3.94

8.34

6.47

6

0.0

1.5

6.22

3.94

8.34

6.47

𝐾

[1/𝑠]
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Finally, the resolution of the domain was varied using 40 different values of nodal
refinement in the depth-wise direction to observe the h-refinement convergence behavior
of the LCMM. These nodal resolutions are given in Table 3 and are recreated here for
convenience. To reiterate, the number of nodes used along the x-coordinate to refine the
nodal density, 𝑛 , is given as a function of case number, 𝑛 , where:
(133)

𝑛 = 3 + 2𝑛

Where 𝑛 ∈ [1, 40]. Given that the length of the domain in the x-coordinate is fixed to
𝐿 = 0.2 𝑐𝑚, the nodal spacing, ℎ, can be calculated as:
ℎ=

𝐿
𝑛

(134)

Table 10: Case number versus number of nodes and spacing in depth-wise coordinate

𝑛

𝑛

ℎ [𝑐𝑚]

1

5

0.04

⁝

⁝

⁝

21

45

0.008

22

47

0.00444

23

49

0.004255

⁝

⁝

⁝

40

83

0.00241

4.1.2. Descriptive Statistics
To compare the two solutions, the Normalized Root Mean Square Error (NRMSE) is
employed. The NRMSE is formulated such that:
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1
∑ [𝑐 (𝒙𝒊 ) − 𝑐 (𝒙𝒊 )]
𝑁
𝑁𝑅𝑀𝑆𝐸 =
|𝑚𝑎𝑥[𝑐 (𝒙𝒊 )] − 𝑚𝑖𝑛[𝑐 (𝒙𝒊 )]|

(135)

Where:
𝑐 (𝒙) = Analytical solution unbound concentration [𝑚𝑔/𝑚𝐿]
𝑐 (𝒙) = Numerical solution unbound concentration [𝑚𝑔/𝑚𝐿]
𝑁 = Number of data points in the matrix of solution values
The NRMSE was the metric of choice, as 1) It is an extension of the Frobenius norm, and
therefore gives an indication of the distance between two matrices of solutions, 2) It is
normalized by the number of data points in the solution, and therefore should not by
swayed by the resolution of the solution as it changes per the convergence study, and 3)
It is normalized by the span of the analytical solution, meaning that the choice of
boundary conditions should not affect the measure of error from any particular case to
another [87].
Recall that Ding et al. defines the convergence rate of locally collocated methods as
being on the order of 𝑂((ℎ/𝑐) ), where [54]:
ℎ = Mesh size, i.e. 1D problem with domain, length 𝐿, with 𝑚 elements, ℎ = 𝐿/𝑚
𝑐 = RBF Shape Factor
𝑛 = Positive constant, determined by number of collocation points in the topology
Given that the shape factor is optimized for each topology in this implementation, it is
worth noting the average shape factor across all topologies, 𝑐 . Note that the shape factor
is generally consistent across the domain, with small deviations at topologies near
boundaries, as depicted in Figure 19. Additionally, it will be worth noting the number of
collocation points used for the interpolation within each topology. Given that the shape
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factor is optimized in an automated fashion, one will note similarities between the shape
factor for a topology and the number of supporting nodes within that topology, also
depicted in Figure 19.

Figure 19: (a) Distribution of shape factors across all topologies and resulting average shape
factor and (b) Number of supporting nodes within a topology

4.1.3. Experimental Results
A side-by-side of the numerical solution to the analytical solution is given for one case at
one time step for a qualitative depiction of the accuracy of the solution.

Figure 20: Comparison of the numerical solution to the analytical solution at 𝑡 = 4 ℎ𝑟𝑠, for the
set of pharmacokinetic parameters, case 1. Note that the NRMSE is a depicted as a percent.
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For each pair of the above six cases, the trend of NRMSE versus nodal resolution is given
graphically below in Figure 21 and Figure 22. For compactness, the cases are grouped
and graphed based on their inclusion of metabolism, that is, cases 1, 3 and 5 from Table 9
are included in one plot, with cases 2, 4 and 6 in the following plot. This grouping is
repeated in all subsequent plots.
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Figure 21: NRMSE versus nodal resolution for coefficient sets with metabolism
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Figure 22: NRMSE versus nodal resolution for coefficient sets without metabolism
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As a note for later discussion on convergence error, it is worth plotting this convergence
behavior in log-log scale versus the average spacing of the solution to elaborate on the hrefinement behavior of the method.
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Figure 23: NRMSE versus average spacing for coefficient sets with metabolism in log-log scale
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Figure 24: NRMSE versus average spacing for coefficient sets without metabolism in log-log
scale
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The NRMSE can be plotted versus the average number of supporting nodes used for
interpolation within a topology and versus the average shape factor over the solution, to
elaborate on the c-refinement behavior of the method.
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Figure 25: NRMSE versus average number of supporting nodes per topology for coefficient sets
with metabolism
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Figure 26: NRMSE versus average number of supporting nodes per topology for coefficient sets
without metabolism
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Figure 27: NRMSE versus average shape factor for coefficient sets with metabolism
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Figure 28: NRMSE versus average shape factor for coefficient sets without metabolism

Finally, it is worth noting that the average shape factor for a solution is affected by the
number of nodes in the solution. This is entirely a consequence of the optimization
routine that was implemented by the author; any researcher can simply implement a
common shape factor across the solution, as is common practice, and will not observe the
same behavior. As this relationship is entirely based on the geometry of the problem, all
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cases of shape factor versus nodal resolution are represented by the same trend and given
below in Figure 29.
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Figure 29: Average shape factor versus the nodal density of the solution; Anderson case,
representative of all cases

4.1.4. Discussion of Results
Recall from Madych that the approximation error for the global collocation MQ method
is on the order of 𝑂 𝑒 𝜆

/

. For localized methods, a theoretical error bound has been

developed, however, an experimentally developed convergence rate is given by Ding et
al., estimating the error to be on the order of 𝑂((ℎ/𝑐) ), with the exponent, 𝑛, being
dependent on the number of supporting nodes in the topology, 𝑛 . The convergence plot
in the linear scale, given in Figure 21 and Figure 22, demonstrates the accuracy of the
LCMM, achieving 1% error or less relative to the analytical solution at only 10 nodes.
While this is incredible in and of itself, more importantly, notice the convergence plots in
the log-log scale in Figure 23 and Figure 24; the relationship between the NRMSE and
the spacing, ℎ, is linear, indicative of the superconvergent behavior of the LCMM [54].
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Additionally, there is an interesting and complex relationship between the average
number of nodes in the topology, average shape factor, and therefore the solution
accuracy. This is partly due to the automated shape factor optimization that is
implemented in the LCMM and may not be as entangled in implementations without a
shape factor optimization. Irrespective of this complexity and of primary importance, as
the shape factor increases, there is an increase in the solution accuracy, noted across all
sets of pharmacokinetic parameters. This is expected behavior and indicative of the crefinement strategy as discussed above. Of course, there is also an improvement in the
approximation error as the number of supporting nodes in the topologies increases,
behavior that is also predicted by Ding’s estimate of the locally collocated convergence
rate [54]. The unique aspect of the solution convergence is that as the nodal density
increases, as evidenced by Figure 29, the average shape factor increases because of the
shape factor optimization. This slightly conflates the refinement strategies, which is
beneficial in that it compounds the accuracy improvements from each strategy, however,
is detrimental to isolating the contribution from each strategy on the overall accuracy of
the LCMM. Regardless, these are great indicators for the convergence of the LCMM and
the relatively low refinement required for an accurate numerical solution.
4.2. Sensitivity Study
The sensitivity study is a fairly quantitative experiment; the numerical method is run over
several sets of pharmacokinetic that are varied in a structured manner to observe how a
change in parameters can affect change in the solution. To that end, there are no real
descriptive statistics that are taken over the solution, as changes in the solutions behavior
are fairly apparent from visual observations.
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4.2.1. Experimental Setup
Before beginning, the governing equations are reproduced here for the convenience of the
reader, such that they can be readily referenced henceforth, with the modification of
using the volume ratio as opposed to 𝑉 and 𝑉 .
𝜕𝑐
= 𝐷𝛻 𝑐 + (𝐾 𝑐 𝜈 − 𝐾 𝑐) − 𝐾 𝑐
𝜕𝑡
𝜕𝑐
1
= 𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝜈

(136)
(137)

−𝐾 𝑐

Where:
𝜈 =

𝑉
𝑉

(138)

The domain is setup to reflect the inverse problem, with a depth of the domain equal to
the average dermal thickness in the face, 0.12 cm [93]. The width of the domain is
arbitrary, but is wide enough to allow the uninhibited diffusion of the compound through
the dermis, and so was set to 1.0 cm. The boundary conditions are fairly simple and
tabulated below in Table 11.
Table 11: Boundary conditions for sensitivity study

Location

Description

Boundary Type

Value

𝑐(𝑥, 0, 𝑡)

Dermal bed

First-kind

0 mg/mL

𝑐(𝑥, 𝐿, 𝑡)

Stratum corneum barrier

Second-kind

0 mg/cm4

𝑐(0, 𝑦, 𝑡)

Symmetry

Second-kind

0 mg/cm4

𝑐(𝑋, 𝑦, 0)

Symmetry

Second-kind

0 mg/cm4

The initial condition is representative of a dermal treatment, where compound is injected
into the skin using a 33-gauge needle and allowed to diffuse freely, depicted in Figure 30.
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Figure 30: Initial condition for sensitivity study

Verapamil is used to provide a baseline set of pharmacokinetic coefficients for the
sensitivity study, with each parameter varied by one order of magnitude to note any
differences in transport behavior. The sets of pharmacokinetic parameters are given
below in Table 12. Each of the below cases is run and compared to the baseline.
Table 12: Sets of pharmacokinetic parameters for sensitivity study

𝐷 [𝑐𝑚 /𝑠]

𝐾 [1/𝑠]

𝐾 [1/𝑠]

𝐾 [1/𝑠]

(x10-8)

(x10-4)

(x10-4)

(x10-4)

(x10-4)

Baseline

7.8

5.61

1.5

6.22

3.94

0.1

1

0.78

5.61

1.5

6.22

3.94

0.1

2

78.0

5.61

1.5

6.22

3.94

0.1

3

7.8

0.561

1.5

6.22

3.94

0.1

4

7.8

56.1

1.5

6.22

3.94

0.1

5

7.8

5.61

0.15

6.22

3.94

0.1

6

7.8

5.61

15.0

6.22

3.94

0.1

7

7.8

5.61

1.5

0.622

3.94

0.1

8

7.8

5.61

1.5

62.2

3.94

0.1

9

7.8

5.61

1.5

6.22

0.394

0.1

10

7.8

5.61

1.5

6.22

39.4

0.1

11

7.8

5.61

1.5

6.22

3.94

0.01

12

7.8

5.61

1.5

6.22

3.94

1.0

𝐾

[1/𝑠]

𝜈 [−]
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4.2.2. Experimental Results
For each of the cases defined above, a snapshot of the field concentration is provided at
the same time step, 𝑡 = 4 ℎ𝑟𝑠. Each of the snapshots are captioned with the case number
and with the pharmacokinetic parameter that is being varied, with a superscript (-) or
superscript (+) indicating whether the parameter is one order of magnitude smaller or
larger than in the baseline case. For example, case 1 will be denoted with the parameter
𝐷 , to indicate that the diffusion coefficient is one order of magnitude smaller than in the
baseline case.

Figure 31: Sensitivity Study: Baseline

Figure 32: Sensitivity Study: Case 1, 𝐷

Figure 33: Sensitivity Study: Case 2, 𝐷
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Figure 34: Sensitivity Study: Case 3, 𝐾

Figure 35: Sensitivity Study: Case 4, 𝐾

Figure 36: Sensitivity Study: Case 5, 𝐾

Figure 37: Sensitivity Study: Case 6, 𝐾
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Figure 38: Sensitivity Study: Case 7, 𝐾

Figure 39: Sensitivity Study: Case 8, 𝐾

Figure 40: Sensitivity Study: Case 9, 𝐾

Figure 41: Sensitivity Study: Case 10, 𝐾
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Figure 42: Sensitivity Study: Case 11, 𝜈

Figure 43: Sensitivity Study: Case 9, 𝜈

4.2.3. Discussion of Results
The results of the sensitivity study will be discussed on a parameter-by-parameter basis.
Diffusion Coefficient - 𝑫
Of course, the effects of varying the diffusion coefficient on the solution are obvious.
Decreasing the diffusion coefficient results in a decrease in the permeability of the
compound and increasing the diffusion coefficient has the opposite effect. In compounds
with low diffusion coefficients, this can result in “hotspots,” areas where the
concentration of the compound is relatively localized. This can have consequences in the
implementation of certain therapies and application approaches, such as that therapy
which originated this research. If the desire is to use a microneedle array to distribute a
uniform concentration distribution in the skin, then the array may need to have more
regularly distributed microneedles to prevent hotspots in compounds with low diffusion
coefficients. Alternatively, in compounds with a higher diffusion coefficient, one can
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benefit from a sparser and potentially cheaper microneedle array and still arrive at a
relatively uniform distribution of the compound.
Metabolic Rate Constant - 𝑲𝒎
From the clinical side, it can be of interest to quantify the amount of a compound that has
been metabolized by the system, as this may be the beginning of the physiological
mechanism of action of the compound. From the mathematical perspective, the metabolic
rate constant impacts the rate at which the compound being transported exits the system.
This behavior is easily observable in the above plots. In case 3, where the metabolic rate
constant is lower, denoted in Figure 34, the quantity of compound still available to
diffuse through the dermis is about 2 orders of magnitude greater than in the baseline
case. The opposite is true in case 4, Figure 35, where the metabolic rate constant is
greater than in the baseline case, with about 2 orders of magnitude less compound than in
the baseline case. Interestingly, when the metabolic rate constant is fairly high, it seems
to almost lessen the diffusion coefficient, as there is a reduction in the unbound
concentration, and therefore the greatest portion of compound is in the bound
compartment.
Elimination Rate Constant - 𝑲𝒆
The elimination rate constant serves a similar function as the metabolic rate constant as it
behaves as a sink to remove compound from the domain. Similar to the metabolic rate
constant, as the elimination rate constant is decreased, the total concentration in the
domain is increased, and as the elimination rate constant is increased, the total
concentration is decreased. However, changes in the elimination rate constant do not have
as significant of an impact on the solution as changes in the metabolic rate constant. This
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is likely due to the fact that clearance effects follow first-order kinetics, and therefore,
elimination effects may be mitigated, at least in part, by adsorption and preferential
arrangement. Interestingly, however, increasing the elimination rate constant does not
seem to impact the diffusive transport of the compound, which is juxtaposed to the effect
that the metabolic rate constant has on the transport of the compound.
Unbinding Rate Constant - 𝑲𝟏𝟐
The unbinding rate constant defines the rate at which compound “moves” from the bound
compartment to the unbound compartment. By decreasing the unbinding rate constant
there is less of the compound that is made available to the unbound compartment. This
effectively serves to reduce the diffusion rate of the compound, as this increases the
proportion of the compound stored in the bound compartment, where it is inhibited from
diffusing freely. Increasing the unbinding rate constant has the opposite effect, where a
greater proportion of the compound is made accessible to the unbound compartment, and
therefore can diffuse more freely through the domain. This seems to accelerate the
elimination of the compound from the domain, as (1) more compound is accessible to be
metabolized, and (2) the compound can more effectively reach the sink boundary
condition at the dermal bed, clearing the compound from the dermis.
Binding Rate Constant - 𝑲𝟐𝟏
The binding rate constant serves as the antagonist to the unbinding rate constant making
the compound more accessible to the bound compartment and less available in the
unbound compartment. Again, as a greater proportion of the compound is bound, it is less
able to diffuse through the domain.
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Volume Ratio - 𝝂𝒃
Interestingly, the volume ratio has no effect on the transport behavior of the compound
relative to the baseline case. This is likely due to the fact that the binding and unbinding
rate constants are both proportional and inversely
4.3. Inverse Problem – Parameter Identification
The inverse problem is aimed at determining the diffusion coefficient of a compound, 𝐷,
presented in the complete set of coupled PDEs governing the dermal transport
phenomenon.
𝜕𝑐
𝑉
= 𝐷𝛻 𝑐 + 𝐾 𝑐
−𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉
𝜕𝑐
𝑉
= 𝐾 𝑐 −𝐾 𝑐
𝜕𝑡
𝑉

−𝐾 𝑐

(139)

(140)

This is accomplished by creating a second, reduced complexity model, which will hereby
be referred to as the “free-diffusion model,” that only accounts for diffusion effects and is
given below in equation (141).
𝜕𝑐
=𝐷
𝜕𝑡

𝛻 𝑐

(141)

The diffusion coefficient of the free-diffusion model is determined entirely by the
molecular weight of the compound being transported. The concentration of the freediffusion model, 𝑐 , is an analogue of, and can therefore be compared to, the
concentration of the complete model, 𝑐. The effective diffusion coefficient, 𝐷, as subject
to elimination and binding effects, is difficult to ascertain experimentally, but the freediffusion coefficient, 𝐷

, is easily calculated from an empirical relationship. It is

presumed that minimizing the span between the free-diffusion concentration, 𝑐 , and the
true concentration distribution, 𝑐, will yield the value of the effective diffusion
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coefficient, 𝐷. This provides a simple in-silico study that can be easily extended to
clinical research for characterizing novel compounds, which is a problem at the core of
the research that motivated this work.
However, in this “first cut” at identifying the effective diffusion coefficient, a significant
shortcoming in the free-diffusion model is identified: elimination effects need to be
considered. Thus, equation (141) is modified by including elimination effects and appears
as:
𝜕𝑐
=𝐷
𝜕𝑡

𝛻 𝑐 − 𝐾𝑐

(142)

𝐾
𝜈 (1 + 𝐾 )

(143)

Where:
𝐾 =𝐾 +𝐾

This modified version of the free-diffusion model is referred to henceforth as the
“extended free-diffusion model,” and is used instead of the free-diffusion model for
inversely identifying the effective diffusion coefficient, 𝐷, with a significant
improvement in results.
4.3.1. Experimental Setup
Two equivalent problems transporting Verapamil through the facial dermis are setup.
Both problems are subject to the same domain, initial conditions, boundary conditions
and transport the same compound. The distinction between the models lies in the
governing equation used to transport Verapamil through the respective domains. The first
model is the complete model, defined by the governing equations given in (139) and
(140). The second model is the free-diffusion model defined by equation (141). From the
literature, Verapamil has a diffusion coefficient of [15]:
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𝐷 = 7.8 ∙ 10

[𝑐𝑚 /𝑠]

(144)

The molecular weight of Verapamil is given in Daltons as [94]:
𝑀𝑊 = 454.6 [𝐷𝑎]

(145)

Which, according to equation (107), yields a free-diffusion coefficient of:
𝐷

= 1.067 ∙ 10

[𝑐𝑚 /𝑠]

(146)

The domains of both problems are given as the following 2D domain, with a depth of 1.2
cm, simulating the average thickness of dermal tissue in the face, and a width of 1.0 cm
[93]. Replicating the sensitivity study, the initial condition is given as the same initial
injection of Verapamil at 30 mg/mL into the middle of the dermis by a 33-gauge needle.

Figure 44: Inverse problem domain and initial condition

The boundary conditions for the inverse problem likewise replicate those conditions
given in the sensitivity study and are as follows. Again, an insulative boundary is given at
the interface with the stratum corneum, preventing “back-diffusion,” given its relative
impermeability [15].
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Table 13: Boundary conditions applied to inverse problem

Location

Description

Boundary Type

Value

𝑐(𝑥, 0, 𝑡)

Dermal bed

First-kind

0 mg/mL

𝑐(𝑥, 𝐿, 𝑡)

Stratum corneum barrier

Second-kind

0 mg/cm4

𝑐(0, 𝑦, 𝑡)

Symmetry

Second-kind

0 mg/cm4

𝑐(𝑋, 𝑦, 0)

Symmetry

Second-kind

0 mg/cm4

With two separate models, the golden section search (GSS) algorithm is employed to
iterate over values for the effective diffusion coefficient, 𝐷, to minimize the difference
between the unbound concentration of the complete transport model, 𝑐, and the
concentration of the extended free-diffusion model, 𝑐 .
The GSS requires an initial set of bounds for the diffusion coefficient, 𝐷

,

,𝐷

to constrain the search of the problem. These initial estimates are given such that:
𝐷

= 1.0 ∙ 10

[𝑐𝑚 /𝑠]

(147)

𝐷

= 1.0 ∙ 10

[𝑐𝑚 /𝑠]

(148)

It is presumed that the GSS will converge on a diffusion coefficient bounded on one side
by the free-diffusion coefficient, estimated at 𝐷

= 1.067 ∙ 10

[𝑐𝑚 /𝑠], and

bounded on the other side by the true diffusion coefficient for Verapamil, 𝐷 = 7.8 ∙
10

[𝑐𝑚 /𝑠]. Allowing for one order of magnitude of variation on this theoretically

boundary provided the initial estimate for 𝐷

and 𝐷

.

4.3.2. Descriptive Statistics
To quantify the difference between the two concentration solutions, the L2-norm is
employed, defined such that:
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𝐿 =

1
𝑁

𝑐(𝒙𝒊 ) − 𝑐 (𝒙𝒊 )

(149)

4.3.3. Experimental Results
Initially implementing the simpler free-diffusion model, the GSS converged on a value
for the effective diffusion coefficient, 𝐷, such that:
𝐷 = 1.566 ∙ 10

[𝑐𝑚 /𝑠]

(150)

This yields the following L2-norm between the complete model and free-diffusion model:
𝐿 = 0.145 [𝑚𝑔/𝑚𝐿]

(151)

Visualizing these solutions at the time step, 𝑡 = 1 ℎ𝑟.:

Figure 45: Comparison of the complete model to the free-diffusion model, employing the
effective diffusion coefficient identified by the free-diffusion minimization

Next, the extended free-diffusion model is implemented, with the GSS converging on a
value for the effective diffusion coefficient, 𝐷, such that:
𝐷 = 7.457 ∙ 10

[𝑐𝑚 /𝑠]

(152)

This yields the following L2-norm between the complete model and the extended freediffusion model:
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𝐿 = 0.00278 [𝑚𝑔/𝑚𝐿]

(153)

Visualizing these solutions at the time step, 𝑡 = 1 ℎ𝑟.:

Figure 46: Comparison of the complete model to the extended free-diffusion model, employing
the effective diffusion coefficient identified by the extended free-diffusion minimization

4.3.4. Discussion of Results
As the field solution of the free-diffusion models are used to inform the diffusion
coefficient of the true model, it’s expected that there should be some agreement between
the field solutions. As a matter of course, while inverse problems are complex and some
solutions can be non-intuitive, the results of a well-posed inverse should have some
indicators of the fitness of the solution.
Free-Diffusion Model
When leveraging the simple free-diffusion model to identify the diffusion coefficient, we
arrive at a value of 𝐷 = 1.566 ∙ 10

[𝑐𝑚 /𝑠] with an L2-norm of 𝐿 = 0.145 [𝑚𝑔/𝑚𝐿].

The value for the diffusion coefficient seems to be within a reasonable range of expected
values, however the L2-norm is somewhat large for a comparable solution, especially in
seeing how accurate the LCMM. However, as this is the first approach taken, there does
not exist any context of what the L2-norm should evaluate to.
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To get a better understanding of the performance of free-diffusion model in identifying
the diffusion coefficient, the solutions are visualized at the same time step, and this is
given in Figure 45. Plotting the results of the two models side-by-side, there is a
significant discrepancy in the field solutions. First, the spatial variation of the
concentration is entirely different indicating that the diffusion coefficient is much smaller
than should be expected, and second, the concentration of the compound with the domain
is off by nearly an order of magnitude. Recall also that the above solutions begin with the
same initial mass of Verapamil within the domain. Therefore, the differences in the field
must in some way arise from the elimination effects, which pose the only method by
which compound exits the system, excluding the sink boundary condition, and which
were ignored in the free-diffusion model. It can be inferred that the GSS is electing to
minimize the diffusion coefficient in order to minimize the quantity of Verapamil exiting
the domain at the sink boundary, to counteract mass which is lost to elimination effects.
This inference is supported in part by the definition of the fitness/objective function,
which is defined explicitly using the compound concentration.
It appears that it is imperative to modify the free-diffusion model in order to account for
elimination effects, such as metabolism and blood elimination. Based also on visual
observation, it is also recommended to consider substance flux as part of the objective
function, such that the spatial variation of the solution concentration can be better
approximated in the domain. Accounting for flux effects may impose a competing
objective; that is, reducing the error in the flux field may increase the error in the
concentration field, as there is only a single design variable. As with any compromise,
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excellent performance in a single metric is given up in exchange for good performance
across many metrics, a jack-of-all-trades concept.
Extended Free-Diffusion Model
When implanting the extended free-diffusion model to identify the diffusion coefficient,
we arrive at a value of 𝐷 = 7.457 ∙ 10

[𝑐𝑚 /𝑠] with an L2-norm of 𝐿 =

0.00278 [𝑚𝑔/𝑚𝐿]. This represents an enormous improvement in the resulting field
solution, an almost 50-fold increase in the similarity between the field solutions. These
field solutions are depicted side-by-side in Figure 46. Additionally, the inversely
identified diffusion coefficient is much closer to the actual diffusion coefficient obtained
from literature, when implementing the extended free-diffusion model. In the case of the
simple free-diffusion model, there is approximately a 101% error on the identified
diffusion coefficient, as compared to the extended free-diffusion model, yielding only a
4.4% error in identifying the diffusion coefficient. This substantiates the claim that
elimination effects are an important consideration when quantifying dermal transport
phenomena.
4.4. Volume-of-Fluid Method
The VOF application of the LCMM yields only qualitative results with respect to the
findings of this study, demonstrating the effectiveness of the LCMM in handling VOF
type problems. The progressive piping process is driven to a large extent by the pumping
mechanism caused by transient hydrodynamics. The classical benchmark problem of the
instantaneous dam-breaking in a “sloshing” tank is chosen for this purpose, and is solved
used the LCMM VOF approach, adopting a standard pressure-velocity correction scheme
for the fluid flow problem. This approach has been implemented by the authors in highly-

106
convective flows using the LCMM. Here, the tank is initially filled with air (𝑠 = 0)
everywhere except on the bottom left corner where a block of water (𝑠 = 1) is trapped
by a dam, as seen in Figure 47.

s=0

s=1
Figure 47: Schematic of the initial condition and LCMM point distribution of the dam-breaking
problem

The dam is instantaneously removed at time, 𝑡 = 0 𝑠, allowing the water to slosh around
the tank. Plots of the time-evolution of the solution at time values of 𝑡 = 3, 6, 9, 12 𝑠 in
Figure 48.
t=3s

t=6s

t=9s

t = 12 s

Figure 48: Time-evolution of the dam-breaking problem at 𝑡 = 3, 6, 9, 12 𝑠

A plot of the velocity vectors is also given below in Figure 49, revealing the motion of
the air, as induced by the sloshing of the water.
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Figure 49: Velocity vector plot of the dam-breaking problem solution at 𝑡 = 12 𝑠

Finally, the poroelastic problem of water flow through a compacted sand levee is
evaluated. This problem combines the surging of water to the levee as well as the
progressive piping within the levee due to the pore pressure and stress field. The
trapezoidal portion of the levee is 40 meters in width at the base and 3 meters in width at
the top, with a heigh of 6 meters. The water level on the left-hand side of the levee is 1
meter from the top of the levee. A 3 meter long “pipe” or crack is included 8 meters from
the left-hand corner of the levee. The contour plots of hydrostatic pressure levels and
water flow vectors within the levee and around the pup are shown in Figure 50 after a
steady-state solution is achieved. The time progression of the saturation within the
poroelastic levee is depicted in Figure 51 at 𝑡 = 20, 40, 60, 80, 100, 120 𝑑𝑎𝑦𝑠.

Figure 50: Contour plots of hydrostatic pressure levels and water flow vectors within the levee
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Figure 51: Time progression of the saturation front in the poroelastic levee at 𝑡 =
20, 40, 60, 80, 100, 120 𝑑𝑎𝑦𝑠
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5. Conclusion
The pharmacokinetic problem set is one of relative complexity with a variety of
multiphysics phenomenon to consider, including diffusive effects, elimination effects and
adsorption and partitioning effects associated with the multiple phases of the dermis.
Given this complexity, a numerical approach is sought to the solution of the governing
equations to arrive at a field distribution of the compound concentration in the dermis.
Here, the Localized Collocation Meshless Method (LCMM) finds a novel application to
the modeling of the coupled pharmacokinetic processes describing the diffusion,
adsorption, elimination, and metabolic physics for a compound in the skin. This LCMM
is validated against the 1D analytical solution for the equations that govern substance
transport in the dermis, with the accuracy of the numerical approximation quantified
using NRMSE. As simulation time progresses, one can see that the NRMSE of the
meshless method tends towards an asymptote, demonstrating convergence towards the
analytical solution. This convergent behavior coupled with the relatively insignificant
deviation of the numerical solution from the analytical solution demonstrates the
accuracy of the technique. Additionally, the numerical technique is applied to several
instances of the solution with varying coefficients, demonstrating an insensitivity to input
parameters, and qualifying the robustness of the solution method. This is verified by the
accuracy of the solution, as indicated by a small NRMSE at any point in time for all
combinations of pharmacokinetic parameters, both with and without metabolic effects.
With an analytical solution to the governing equations at hand, a mesh convergence study
elaborates on the behavior of the LCMM with a locally optimized shape parameter for
accuracy, similar to a shape factor optimization scheme proposed by Cheng [67]. From
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this, study, super-convergence of the LCMM with regards to data center resolution is
again demonstrated, confirming results from Ding et al. [54]. This study also
demonstrates how the local optimization scheme implemented attempts to compensate for
a reduced node distribution by adjusting the shape parameters within a topology.
Additionally, the results of this study demonstrate that the greater the number of
supporting nodes to generate the interpolation within a local topology, the greater the
accuracy of the solution. This deduction makes sense; as a collocation strategy includes
more knots within the topology, the strategy approaches a global scheme, which is
spectrally convergent. Observing trends in error with respect to shape parameter and
spacing may further expound on optimal setup and applications of the LCMM. A similar
approach is taken by Cheng, Kansa, Madych and others in quantifying the error
associated with the global collocation technique via numerical experimentation. A
sensitivity study is conducted to evaluate the influence of the pharmacokinetic parameters
on the solution space.
Having established the validity of the numerical technique for pharmacokinetic
applications, it is intended for the LCMM to be applied to the optimization of transdermal
drug delivery. It is of interest to the authors to implement this method as a foundation for
rapidly modelling dermal transport processes for the search of optimized solutions, as
well as for inversely identifying parameters that govern these processes from
experimental data.
The efficiency of the LCMM is leveraged by the Golden Section Search algorithm to
provide a framework for inverse problems, allowing a convenient tool for the parametric
study of computation pharmacokinetic models, at least, in a relatively simple, one-
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dimensional parameter search space. This framework can be extended by other
minimization schemes, such as genetic algorithms, for application to more elaborate
problems, such as the inverse geometry problem of optimal microneedle geometry.
However, for these studies to be valid requires an appropriate modeling strategy, fitness
definition and optimization scheme. Given the non-linearity of the problem, failing to do
so can produce counter-logic results, as evidenced by the first study, whereby the
effective diffusion coefficient is obtained without the implementation of elimination
effects. Within the context of the inverse problem posed here, it was observed that,
without accounting for elimination effects, the search algorithm tends towards lower
effective diffusion coefficients, in order to compensate for elimination effects not
considered in the free-diffusion model. When elimination effects are included, the
accuracy of the effective-diffusion model increases. This improvement in solution
accuracy demonstrates the necessity for the inclusion of elimination effects in the model.
It is interesting to note that the sensitivity study and inverse problem revealed that the
additional bound compartment adds second-order transience effects, while also inhibiting
the diffusion of the compound through binding, as the second compartment has no
diffusive term.
It was hypothesized here that a simple, diffusion-only model may describe enough of the
physics to capture the transport of a substance through the dermis, based on the freediffusion premise offered by Kretsos [20]. However, it is apparent from the results of the
analysis that such a model cannot approximate the solution of the complete diffusion
model accurately if elimination phenomena are not accounted for. Despite the suggestion
that it might be possible to neglect other physical processes and focus solely on free-
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diffusion mechanics, metabolism and elimination effects have too great of a role in the
transport behavior of a compound to be neglected. Presumably, an elimination rate
coefficient may be “small-enough” for elimination effects to be neglected, similar to the
distinction between fast-binding versus slow-binding behavior. It would then be of value
to determine the proportion of diffusion rate coefficient versus elimination rate
coefficient that would yield such behavior.
However, it appears possible to include a first-order elimination coefficient in the onecompartment, free-diffusion model; a coefficient that accounts for elimination effects in
both compartments as a single term in a modified free-diffusion model. Even this simple
addition provides great strides forward in accuracy, with results of a one-compartment
model becoming more comparable to the two-compartment model. To that end, a onecompartment model that neglects binding effects, as posed by Kretsos, but one that
retains elimination effects, could very well approximate the more complex twocompartment model. This may seem to be regressing to a time before multi-compartment
models; however, the ability to account for the effects of multiple compartments using
only the experimental measures from a single compartment may provide a step forward
in the field of inverse techniques for transdermal drug delivery.
Altogether, it is the hope of the author that this work fleshes out the entirety of the
pharmacokinetic modeling paradigm using locally collocated meshless methods. The
development of the pharmacokinetic model, with a variety of its developments and
considerations have been reviewed and presented. Additionally, the meshless method has
been presented in its entirety, from inception as an interpolation technique and the
fundamentals of its formulation, through the evolution of its implementation and
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collocation strategies, has been presented. The LCMM in particular has been applied to
the pharmacokinetic problem with incredible results, demonstrating accuracy, efficiency
and robustness. This provides a useful tool by which successive studies can be conducted
to further develop transdermal delivery techniques.
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6. Recommendations and Future Work
Thankfully, there are many potential avenues in which this numerical framework can find
application, with a unique development or “twist” for each problem that will be
encountered. In the simplest, perhaps naïve and optimistic case, it is of interest to find
more pharmacokinetic applications to investigate and problems to tackle. However, there
are a handful of topics concerning the fundamentals of meshless methods that, in authors
opinion, warrant further study.
First and foremost of these recommended topics would be further studies on the
convergence behavior of the LCMM. It is generally accepted that when local collocation
is used instead of global collocation, accuracy in the form of spectral convergence is
sacrificed for the sake of solution stability. This relationship between convergence and
stability is a commonly accepted fact, with acknowledgment by the community that
locally collocated meshless methods still outperform traditional meshed methods with
regards to accuracy, thereby turning local collocation meshless into the preeminent
method of numerical techniques. Despite this acceptance, there are still unknowns with
regards to how well the LCMM performs in convergence; excluding this work, the author
has thus far found only one other paper evaluating the convergence performance of the
LCMM. While the work here has shown agreement with these experimental results,
confirming, to a degree, the super convergent behavior of the LCMM, it is not as granular
of a study as would be required to truly derive empirical formulae. That is, the validation
and convergence effort given here prioritized the accuracy of the solution, leveraging
several techniques at once to arrive at this goal. As analytical definitions of the local
collocation’s convergence are non-existent, empirical formulae can potentially be derived
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from in silico studies and other numerical experiments. To do so requires an assiduous
experimental approach to isolate the effects of every parameter impacting the accuracy of
the numerical solution; ideally this would also include a variety of problems to be
evaluated against in multiple dimensions.
Considers the extremes of local collocation, either 1) Topologies large enough to capture
every point in the domain or 2) Topologies small enough that no other points are
captured. Theoretically, if a locally collocated method used an ever-increasing number of
supporting nodes within a topology, the LCMM would tend towards a globally collocated
method. What happens as the number of supporting nodes approaches the total number of
nodes within the solution? Is there a point that a locally collocated method might
recuperate spectral convergence? What happens if this limit is explored in the converse
and topologies are constructed with one or zero supporting nodes? Does this collapse into
a simple interpolation strategy? Does the governing equations’ complexity dominate the
solution in the form of unknowns and improperly defined constraints? Perhaps
understanding how the method performs in these extremes can illuminate the inner
mechanisms of the LCMM, which might further justify its adoption in industrial settings.
It is the authors opinion that these are problems worth investigating, for the sake of
developing these tools further, perhaps, to “optimize” how the LCMM is used.
As noted above, inverse geometry problems pose some grievance with respect to
numerical techniques. Meshed methods may not be particularly robust in handling these
inverse methods, given the significant effort of model preparation and mesh generation.
Meshless methods propose can mitigate many of these instabilities, but still requires the
recalculation of certain parameters as domains and topologies change. Therefore, it may
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be useful to further pursue techniques to mitigate recalculating topology data in problems
where domains and nodes can be moving; consider contact problems or problems
concerning fracture mechanics. The Volume-of-Fluid approach was one such method that
was advantageous to the piping problem and may likewise find application to
microneedle optimization. Is it truly inevitable that the topologies of domains must be
reconstructed in such work, or are there ways to mitigate these issues and more fully
automate the meshless framework? Perhaps not. There is at least one method for handling
moving domains, and this can potentially field many robust solution approaches which
can find application to a wide set of problems, including but not limited to
pharmacokinetics and transdermal drug delivery.
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8. Appendix A
A. Compound molecular weight, versus effective and free-diffusion coefficient
Table 14: Compound molecular weight, effective, and free diffusion coefficient [20]

𝐷

MW [𝐷𝑎]

𝐷

Water

18.0

60.0

106.6

Methanol

32.0

67.0

73.1

Ethanol

46.1

57.0

57.6

Propanol

60.1

50.0

48.4

Butanol

74.1

48.0

42.2

Pentanol

88.2

27.0

37.6

Hexanol

102.2

16.0

34.2

Heptanol

116.2

9.9

31.4

Octanol

130.2

5.1

29.2

Decanol

158.2

-

25.7

Betamethasone

392.5

7.4

14.2

Betamethasone 17-valerate

476.6

1.6

12.5

Methoxsalen

216.2

7.64

20.9

Glucose

180.2

26.4

23.6

Testosterone

288.4

4.1 ± 0.6

17.3

Hydrocortisone

362.5

2.85

14.9

Salicylic acid

138.1

8±3

28.1

∙ 10 [𝑐𝑚 /𝑠]

∙ 10 [𝑐𝑚 /𝑠]
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Didanosine

236.2

-

19.74

Pentanol

88.2

12.3

37.6

Vidarabine

267.2

9.5

18.2

Vidarabine

267.2

15

18.2

Hypoxanthine arabinoside

267.2

13.8

18.2

Vidarabine-5-n-valerate

351.4

9.7

15.2

Progesterone

314.5

0.41 ± 0.03

16.4

Desoxycorticosterone

330.5

0.53 ± 0.11

15.8

11-α-Hydroxyprogesterone

330.5

0.66 ± 0.14

15.8

17-α-Hydroxyprogesterone

330.5

0.62 ± 0.13

15.8

Corticosterone

346.5

0.44 ± 0.08

15.4

17-α-Hydroxydeoxy-corticosterone

346.5

0.64 ± 0.11

15.4

Hydrocortisone

362.5

0.44 ± 0.07

14.9

Piroxicam

331.4

-

15.8
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B. NRMSE of Analytical Convergence Test Cases
Table 15: NRMSE of Analytical Convergence Test Cases

Case

Coeff. Set 1

Coeff. Set 2

Coeff. Set 3

Coeff. Set 4

Coeff. Set 5

Coeff. Set 6

1

0.03912

0.02797

0.03942

0.03053

0.03936

0.02998

2

0.01720

0.01626

0.01726

0.01625

0.01723

0.01628

3

0.01239

0.01262

0.01239

0.01250

0.01238

0.01257

4

0.01012

0.01038

0.01013

0.01027

0.01011

0.01034

5

0.00856

0.00884

0.00857

0.00872

0.00855

0.00879

6

0.00742

0.00771

0.00743

0.00759

0.00741

0.00765

7

0.00654

0.00684

0.00656

0.00672

0.00654

0.00678

8

0.00586

0.00616

0.00587

0.00604

0.00585

0.00610

9

0.00530

0.00561

0.00531

0.00549

0.00529

0.00554

10

0.00484

0.00515

0.00485

0.00503

0.00483

0.00508

11

0.00445

0.00477

0.00447

0.00464

0.00445

0.00469

12

0.00412

0.00444

0.00414

0.00432

0.00412

0.00437

13

0.00384

0.00416

0.00386

0.00403

0.00383

0.00408

14

0.00359

0.00391

0.00361

0.00379

0.00359

0.00384

15

0.00338

0.00370

0.00339

0.00357

0.00337

0.00362

16

0.00318

0.00351

0.00320

0.00338

0.00318

0.00343

17

0.00301

0.00334

0.00303

0.00321

0.00300

0.00326

18

0.00286

0.00318

0.00288

0.00306

0.00285

0.00311

19

0.00272

0.00304

0.00274

0.00292

0.00271

0.00297

20

0.00259

0.00292

0.00261

0.00279

0.00259

0.00284

21

0.00248

0.00280

0.00250

0.00268

0.00247

0.00273

22

0.00237

0.00270

0.00239

0.00257

0.00237

0.00262

23

0.00228

0.00260

0.00229

0.00248

0.00227

0.00253

24

0.00219

0.00251

0.00221

0.00239

0.00218

0.00244

25

0.00211

0.00243

0.00212

0.00231

0.00210

0.00236
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26

0.00203

0.00235

0.00205

0.00223

0.00202

0.00228

27

0.00196

0.00228

0.00198

0.00216

0.00195

0.00221

28

0.00189

0.00222

0.00191

0.00209

0.00189

0.00214

29

0.00183

0.00215

0.00185

0.00203

0.00182

0.00208

30

0.00177

0.00210

0.00179

0.00197

0.00177

0.00202

31

0.00172

0.00204

0.00174

0.00192

0.00171

0.00197

32

0.00167

0.00199

0.00169

0.00187

0.00166

0.00192

33

0.00162

0.00194

0.00164

0.00182

0.00161

0.00187

34

0.00157

0.00190

0.00159

0.00177

0.00157

0.00182

35

0.00153

0.00185

0.00155

0.00173

0.00152

0.00178

36

0.00149

0.00181

0.00151

0.00169

0.00148

0.00174

37

0.00145

0.00177

0.00147

0.00165

0.00145

0.00170

38

0.00142

0.00173

0.00143

0.00161

0.00141

0.00166

39

0.00138

0.00170

0.00140

0.00158

0.00137

0.00163

40

0.00135

0.00167

0.00136

0.00154

0.00134

0.00159
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C. Average Spacing, Average Number of Supporting Nodes and Average Shape Factor
per Case for Convergence Test Cases
Table 16: Spacing, Supporting Nodes and Shape Factor for Convergence Test Cases

Average

Average Number of

Average

Spacing [cm]

Supporting Nodes

Shape Factor

1

0.04

9.0

13.9

2

0.02857

18.92

12.104

3

0.02222

21.24490

11.15714

4

0.01818

22.82716

10.48395

5

0.01538

23.87603

9.90744

6

0.01333

24.62130

9.50296

7

0.01176

25.17778

9.20356

8

0.01053

25.60900

8.97301

9

0.00952

25.95291

8.79003

10

0.00870

26.23356

8.64127

11

0.00800

26.46692

8.51796

12

0.00741

26.66400

8.41408

13

0.00690

26.83265

8.32538

14

0.00645

26.97860

8.24875

15

0.00606

27.10614

8.18189

16

0.00571

27.21855

8.12305

17

0.00541

27.31837

8.07086

18

0.00513

27.40760

8.02425

19

0.00488

27.48784

7.98238

20

0.00465

27.56038

7.94456

21

0.00444

27.62628

7.91022

22

0.00426

27.68642

7.87891

Case
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23

0.00408

27.74151

7.85025

24

0.00392

27.79217

7.82391

25

0.00377

27.83891

7.79962

26

0.00364

27.88216

7.77714

27

0.00351

27.92231

7.75630

28

0.00339

27.95968

7.73690

29

0.00328

27.99454

7.71882

30

0.00317

28.02714

7.70191

31

0.00308

28.05770

7.68607

32

0.00299

28.08639

7.67120

33

0.00290

28.11339

7.65721

34

0.00282

28.13884

7.64402

35

0.00274

28.16286

7.63158

36

0.00267

28.18559

7.61982

37

0.00260

28.20711

7.60868

38

0.00253

28.22753

7.59811

39

0.00247

28.24692

7.58808

40

0.00241

28.26536

7.57854

